[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f4FSuxzbPPUJ1ksnvWdJKFOZw2ZOXxfEHsd2ZN3HHhiw":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":61,"rows":68},"National Institutes of Health Clinical Center (CC)",[4],368,true,33,7,30819078,11,240,[14,16,19,22,25,28,30,32],{"name":15,"count":8},"Healthy",{"name":17,"count":18},"Unspecified Adult Solid Tumor, Protocol Specific",20,{"name":20,"count":21},"Lymphoma",17,{"name":23,"count":24},"Liver Cancer",13,{"name":26,"count":27},"Breast Cancer",12,{"name":29,"count":27},"Melanoma (Skin)",{"name":31,"count":11},"Healthy Volunteers",{"name":33,"count":34},"Kidney Cancer",10,[36,41,46,51,56],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT05691530","Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine","2025-04-23","rDEN3Δ30\u002F31-7164",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05907746","Allogeneic Hematopoietic Stem Cell Transplantation With Briquilimab-Based Conditioning in Participants With GATA2 Deficiency","2025-10-16","Mycophenolate Mofetil",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT01712620","Spironolactone for Pulmonary Arterial Hypertension","2026-12-31","Spironolactone",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT02392442","Effects of Bronchial Segmental Endotoxin Instillation in Humans","2027-06-30","Endotoxin",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT01553214","Improving White Blood Cell Collection From Healthy Donors","2032-01-01","Filgrastim",[62,63,64,65,66,67],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[69,186,215,248,276,294,312,330,351,461,487,509,532,557,583,605,630,657,675,693,720,738,756,787,805,823,841,859,883,958,1003,1029,1055,1081,1107,1129,1151,1173,1195,1217,1235,1253,1271,1329,1381,1411,1455,1502,1528,1559,1601,1627,1662,1684,1713,1735,1761,1787,1817,1839,1861,1889,1907,1925,1946,1971,1996,2021,2039,2057,2075,2101,2129,2147,2172,2198,2216,2234,2252,2275,2293,2311,2336,2362,2380,2398,2416,2442,2464,2482,2500,2526,2551,2569,2587,2605,2629,2653,2677,2726,2762,2792,2814,2845,2863,2881,2904,2925,2943,2966,2989,3007,3030,3048,3077,3095,3113,3131,3156,3174,3198,3216,3238,3263,3281,3299,3329,3347,3365,3383,3407,3425,3443,3461,3484,3505,3523,3545,3570,3588,3614,3632,3650,3668,3686,3704,3722,3740,3758,3776,3794,3819,3844,3867,3885,3907,3925,3946,3973,3991,4016,4034,4052,4075,4100,4123,4169,4211,4239,4278,4308,4330,4357,4379,4401,4422,4449,4467,4490,4512,4536,4562,4584,4616,4634,4652,4670,4688],{"intervention":70,"totalTrials":71,"cells":72},"filgrastim",8,{"EARLY_PHASE1":73,"PHASE1":76,"PHASE2":129,"PHASE3":170,"PHASE4":172,"NA":184},{"trials":74,"activeCount":75},[],0,{"trials":77,"activeCount":75},[78,103,118],{"nctId":79,"briefTitle":80,"status":81,"phases":82,"completion":83,"start":84,"enrollment":18,"conditions":85,"interventions":91},"NCT00080925","T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies","COMPLETED",[63],"2010-12","2004-02",[86,87,20,88,89,90],"Chronic Myeloproliferative Disorders","Leukemia","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic Syndromes","Myelodysplastic\u002FMyeloproliferative Neoplasms",[70,92,93,94,95,96,97,98,99,100,101,102],"graft-versus-tumor induction therapy","rituximab","therapeutic allogeneic lymphocytes","cyclophosphamide","cyclosporine","cytarabine","doxorubicin hydrochloride","etoposide","fludarabine phosphate","prednisone","vincristine sulfate",{"nctId":104,"briefTitle":105,"status":81,"phases":106,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":112},"NCT00091104","Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Aldesleukin in Treating Patients With Metastatic Melanoma",[63],"2010-08","2010-10","2004-07",136,[29],[113,114,70,115,116,117,95,100],"MART-1:27-35 peptide vaccine","aldesleukin","incomplete Freund's adjuvant","therapeutic autologous lymphocytes","therapeutic tumor infiltrating lymphocytes",{"nctId":119,"briefTitle":120,"status":81,"phases":121,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":126,"interventions":127},"NCT00085462","Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma",[63],"2007-05","2008-09","2004-05",61,[29],[114,70,128,116,117,95,100],"gp100-fowlpox vaccine",{"trials":130,"activeCount":75},[131,141,150,161],{"nctId":132,"briefTitle":133,"status":134,"phases":135,"completion":136,"start":137,"enrollment":138,"conditions":139,"interventions":140},"NCT00138229","Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma","TERMINATED",[64],"2007-04","2005-07",6,[29],[114,70,116,95,100],{"nctId":142,"briefTitle":143,"status":81,"phases":144,"primaryCompletion":145,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":149},"NCT00096382","Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma",[64],"2009-01","2004-09",34,[29],[114,70,117,95,100],{"nctId":151,"briefTitle":152,"status":134,"phases":153,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":157,"interventions":158},"NCT00704938","Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer",[64],"2009-08","2008-06",3,[33,29,17],[114,159,160,70,95,100],"anti-p53 T-cell receptor-transduced peripheral blood lymphocytes","autologous dendritic cell-adenovirus p53 vaccine",{"nctId":162,"briefTitle":163,"status":81,"phases":164,"primaryCompletion":165,"completion":123,"start":166,"enrollment":8,"conditions":167,"interventions":168},"NCT00062036","Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma",[63,64],"2007-02","2003-06",[29],[114,70,115,169,117,95,100],"interleukin-2 gene",{"trials":171,"activeCount":75},[],{"trials":173,"activeCount":183,"soonestReadout":59},[174],{"nctId":57,"briefTitle":58,"status":175,"phases":176,"primaryCompletion":59,"completion":59,"start":177,"enrollment":178,"conditions":179,"interventions":181},"RECRUITING",[66],"2012-12-31",1000,[180],"Allogeneic Granulocyte Donation",[60,182],"Dexamethasone",1,{"trials":185,"activeCount":75},[],{"intervention":182,"totalTrials":187,"cells":188},2,{"EARLY_PHASE1":189,"PHASE1":191,"PHASE2":203,"PHASE3":205,"PHASE4":207,"NA":213},{"trials":190,"activeCount":75},[],{"trials":192,"activeCount":75},[193],{"nctId":194,"briefTitle":195,"status":81,"phases":196,"completion":197,"start":198,"enrollment":199,"conditions":200,"interventions":201},"NCT00001842","G-CSF for Granulocyte Donation",[63],"2002-06","1999-07",16,[15],[202,182],"Granulocyte colony-stimulating factor",{"trials":204,"activeCount":75},[],{"trials":206,"activeCount":75},[],{"trials":208,"activeCount":183,"soonestReadout":59},[209],{"nctId":57,"briefTitle":58,"status":175,"phases":210,"primaryCompletion":59,"completion":59,"start":177,"enrollment":178,"conditions":211,"interventions":212},[66],[180],[60,182],{"trials":214,"activeCount":75},[],{"intervention":55,"totalTrials":187,"cells":216},{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":232,"PHASE3":242,"PHASE4":244,"NA":246},{"trials":218,"activeCount":75},[],{"trials":220,"activeCount":75},[221],{"nctId":222,"briefTitle":223,"status":81,"phases":224,"primaryCompletion":225,"completion":225,"start":226,"enrollment":227,"conditions":228,"interventions":230},"NCT00094406","Carbon Monoxide to Prevent Lung Inflammation",[63],"2010-03-11","2004-10-13",35,[229],"Respiratory Distress Syndrome, Adult",[55,231],"Carbon Monoxide",{"trials":233,"activeCount":183,"soonestReadout":54},[234],{"nctId":52,"briefTitle":53,"status":235,"phases":236,"primaryCompletion":54,"completion":54,"start":237,"enrollment":238,"conditions":239,"interventions":241},"ENROLLING_BY_INVITATION",[64],"2015-06-18",58,[240],"Acute Lung Inflammation",[55],{"trials":243,"activeCount":75},[],{"trials":245,"activeCount":75},[],{"trials":247,"activeCount":75},[],{"intervention":45,"totalTrials":183,"cells":249},{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":254,"PHASE3":270,"PHASE4":272,"NA":274},{"trials":251,"activeCount":75},[],{"trials":253,"activeCount":75},[],{"trials":255,"activeCount":183,"soonestReadout":44},[256],{"nctId":42,"briefTitle":43,"status":257,"phases":258,"primaryCompletion":44,"completion":259,"start":260,"enrollment":24,"conditions":261,"interventions":264},"ACTIVE_NOT_RECRUITING",[64],"2028-07-31","2023-11-29",[262,263],"GATA2","Immunodeficiency",[45,265,266,267,268,269],"Tacrolimus","Post-Transplant Cyclophosphamide","Briquilimab","Cyclophosphamide","Fludarabine",{"trials":271,"activeCount":75},[],{"trials":273,"activeCount":75},[],{"trials":275,"activeCount":75},[],{"intervention":265,"totalTrials":183,"cells":277},{"EARLY_PHASE1":278,"PHASE1":280,"PHASE2":282,"PHASE3":288,"PHASE4":290,"NA":292},{"trials":279,"activeCount":75},[],{"trials":281,"activeCount":75},[],{"trials":283,"activeCount":183,"soonestReadout":44},[284],{"nctId":42,"briefTitle":43,"status":257,"phases":285,"primaryCompletion":44,"completion":259,"start":260,"enrollment":24,"conditions":286,"interventions":287},[64],[262,263],[45,265,266,267,268,269],{"trials":289,"activeCount":75},[],{"trials":291,"activeCount":75},[],{"trials":293,"activeCount":75},[],{"intervention":266,"totalTrials":183,"cells":295},{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":300,"PHASE3":306,"PHASE4":308,"NA":310},{"trials":297,"activeCount":75},[],{"trials":299,"activeCount":75},[],{"trials":301,"activeCount":183,"soonestReadout":44},[302],{"nctId":42,"briefTitle":43,"status":257,"phases":303,"primaryCompletion":44,"completion":259,"start":260,"enrollment":24,"conditions":304,"interventions":305},[64],[262,263],[45,265,266,267,268,269],{"trials":307,"activeCount":75},[],{"trials":309,"activeCount":75},[],{"trials":311,"activeCount":75},[],{"intervention":267,"totalTrials":183,"cells":313},{"EARLY_PHASE1":314,"PHASE1":316,"PHASE2":318,"PHASE3":324,"PHASE4":326,"NA":328},{"trials":315,"activeCount":75},[],{"trials":317,"activeCount":75},[],{"trials":319,"activeCount":183,"soonestReadout":44},[320],{"nctId":42,"briefTitle":43,"status":257,"phases":321,"primaryCompletion":44,"completion":259,"start":260,"enrollment":24,"conditions":322,"interventions":323},[64],[262,263],[45,265,266,267,268,269],{"trials":325,"activeCount":75},[],{"trials":327,"activeCount":75},[],{"trials":329,"activeCount":75},[],{"intervention":50,"totalTrials":183,"cells":331},{"EARLY_PHASE1":332,"PHASE1":334,"PHASE2":336,"PHASE3":345,"PHASE4":347,"NA":349},{"trials":333,"activeCount":75},[],{"trials":335,"activeCount":75},[],{"trials":337,"activeCount":183,"soonestReadout":49},[338],{"nctId":47,"briefTitle":48,"status":175,"phases":339,"primaryCompletion":49,"completion":49,"start":340,"enrollment":341,"conditions":342,"interventions":344},[64],"2014-01-10",70,[343],"Pulmonary Arterial Hypertension",[50],{"trials":346,"activeCount":75},[],{"trials":348,"activeCount":75},[],{"trials":350,"activeCount":75},[],{"intervention":95,"totalTrials":352,"cells":353},14,{"EARLY_PHASE1":354,"PHASE1":356,"PHASE2":370,"PHASE3":426,"PHASE4":438,"NA":440},{"trials":355,"activeCount":75},[],{"trials":357,"activeCount":75},[358,362,366],{"nctId":79,"briefTitle":80,"status":81,"phases":359,"completion":83,"start":84,"enrollment":18,"conditions":360,"interventions":361},[63],[86,87,20,88,89,90],[70,92,93,94,95,96,97,98,99,100,101,102],{"nctId":104,"briefTitle":105,"status":81,"phases":363,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":364,"interventions":365},[63],[29],[113,114,70,115,116,117,95,100],{"nctId":119,"briefTitle":120,"status":81,"phases":367,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":368,"interventions":369},[63],[29],[114,70,128,116,117,95,100],{"trials":371,"activeCount":183,"soonestReadout":44},[372,382,386,397,410,414,418,422],{"nctId":373,"briefTitle":374,"status":134,"phases":375,"primaryCompletion":376,"completion":376,"start":108,"enrollment":147,"conditions":377,"interventions":380},"NCT01236573","Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes",[63,64],"2015-03",[378,379],"Skin Cancer","Metastatic Melanoma",[269,268,381],"IL-12 transduced TIL",{"nctId":132,"briefTitle":133,"status":134,"phases":383,"completion":136,"start":137,"enrollment":138,"conditions":384,"interventions":385},[64],[29],[114,70,116,95,100],{"nctId":387,"briefTitle":388,"status":134,"phases":389,"primaryCompletion":390,"completion":390,"start":136,"enrollment":27,"conditions":391,"interventions":394},"NCT00482911","Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma",[64],"2009-04",[392,393],"Intraocular Melanoma","Malignant Conjunctival Neoplasm",[95,395,396],"lenalidomide","sunitinib malate",{"nctId":398,"briefTitle":399,"status":81,"phases":400,"completion":401,"start":402,"conditions":403,"interventions":404},"NCT00018954","Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma",[64],"2002-10","1992-10",[87,20],[405,95,97,406,98,99,407,408,409,101,102],"asparaginase","daunorubicin hydrochloride","ifosfamide","mercaptopurine","methotrexate",{"nctId":142,"briefTitle":143,"status":81,"phases":411,"primaryCompletion":145,"completion":145,"start":146,"enrollment":147,"conditions":412,"interventions":413},[64],[29],[114,70,117,95,100],{"nctId":42,"briefTitle":43,"status":257,"phases":415,"primaryCompletion":44,"completion":259,"start":260,"enrollment":24,"conditions":416,"interventions":417},[64],[262,263],[45,265,266,267,268,269],{"nctId":151,"briefTitle":152,"status":134,"phases":419,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":420,"interventions":421},[64],[33,29,17],[114,159,160,70,95,100],{"nctId":162,"briefTitle":163,"status":81,"phases":423,"primaryCompletion":165,"completion":123,"start":166,"enrollment":8,"conditions":424,"interventions":425},[63,64],[29],[114,70,115,169,117,95,100],{"trials":427,"activeCount":75},[428],{"nctId":429,"briefTitle":430,"status":431,"phases":432,"completion":433,"start":434,"enrollment":75,"conditions":435,"interventions":436},"NCT00019409","Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia","WITHDRAWN",[65],"2001-07","1999-10",[87],[405,95,97,406,408,409,101,437,102],"therapeutic hydrocortisone",{"trials":439,"activeCount":75},[],{"trials":441,"activeCount":75},[442,452],{"nctId":443,"briefTitle":444,"status":445,"phases":446,"conditions":447,"interventions":448},"NCT04135092","Single Patient Protocol: A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab","NO_LONGER_AVAILABLE",[],[],[449,268,269,450,451],"Individual Patient TCR Transduced PBL","Aldesleukin","Pembrolizumab",{"nctId":453,"briefTitle":454,"status":431,"phases":455,"completion":456,"start":457,"enrollment":75,"conditions":458,"interventions":459},"NCT00389506","Fludarabine and Cyclophosphamide Followed By LMB-2 Immunotoxin in Treating Patients With Hodgkin's Lymphoma",[67],"2008-05","2006-09",[20],[460,95,100],"LMB-2 immunotoxin",{"intervention":269,"totalTrials":156,"cells":462},{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":477,"PHASE4":479,"NA":481},{"trials":464,"activeCount":75},[],{"trials":466,"activeCount":75},[],{"trials":468,"activeCount":183,"soonestReadout":44},[469,473],{"nctId":373,"briefTitle":374,"status":134,"phases":470,"primaryCompletion":376,"completion":376,"start":108,"enrollment":147,"conditions":471,"interventions":472},[63,64],[378,379],[269,268,381],{"nctId":42,"briefTitle":43,"status":257,"phases":474,"primaryCompletion":44,"completion":259,"start":260,"enrollment":24,"conditions":475,"interventions":476},[64],[262,263],[45,265,266,267,268,269],{"trials":478,"activeCount":75},[],{"trials":480,"activeCount":75},[],{"trials":482,"activeCount":75},[483],{"nctId":443,"briefTitle":444,"status":445,"phases":484,"conditions":485,"interventions":486},[],[],[449,268,269,450,451],{"intervention":40,"totalTrials":183,"cells":488},{"EARLY_PHASE1":489,"PHASE1":491,"PHASE2":501,"PHASE3":503,"PHASE4":505,"NA":507},{"trials":490,"activeCount":75},[],{"trials":492,"activeCount":183,"soonestReadout":39},[493],{"nctId":37,"briefTitle":38,"status":257,"phases":494,"primaryCompletion":39,"completion":495,"start":496,"enrollment":497,"conditions":498,"interventions":500},[63],"2026-05-01","2023-03-07",127,[499],"Response To Dengue Exposure",[40],{"trials":502,"activeCount":75},[],{"trials":504,"activeCount":75},[],{"trials":506,"activeCount":75},[],{"trials":508,"activeCount":75},[],{"intervention":510,"totalTrials":183,"cells":511},"St. John's Wort",{"EARLY_PHASE1":512,"PHASE1":514,"PHASE2":516,"PHASE3":518,"PHASE4":520,"NA":530},{"trials":513,"activeCount":75},[],{"trials":515,"activeCount":75},[],{"trials":517,"activeCount":75},[],{"trials":519,"activeCount":75},[],{"trials":521,"activeCount":75},[522],{"nctId":523,"briefTitle":524,"status":81,"phases":525,"completion":526,"start":527,"enrollment":27,"conditions":528,"interventions":529},"NCT00006395","Drug Interaction Study of Tegretol (Carbamazepine) and St. John's Wort in Normal Volunteers",[66],"2001-04","2000-10",[15],[510],{"trials":531,"activeCount":75},[],{"intervention":533,"totalTrials":183,"cells":534},"Valganciclovir",{"EARLY_PHASE1":535,"PHASE1":537,"PHASE2":539,"PHASE3":541,"PHASE4":543,"NA":555},{"trials":536,"activeCount":75},[],{"trials":538,"activeCount":75},[],{"trials":540,"activeCount":75},[],{"trials":542,"activeCount":75},[],{"trials":544,"activeCount":75},[545],{"nctId":546,"briefTitle":547,"status":81,"phases":548,"primaryCompletion":549,"completion":550,"start":551,"enrollment":27,"conditions":552,"interventions":554},"NCT00034385","Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney\u002FPancreas Transplant Recipients",[66],"2007-01-30","2009-10-30","2002-04-24",[553],"Kidney Trasplant",[533],{"trials":556,"activeCount":75},[],{"intervention":558,"totalTrials":183,"cells":559},"Ledipasvir 90 mg and Sofosbuvir 400 mg",{"EARLY_PHASE1":560,"PHASE1":562,"PHASE2":564,"PHASE3":566,"PHASE4":568,"NA":581},{"trials":561,"activeCount":75},[],{"trials":563,"activeCount":75},[],{"trials":565,"activeCount":75},[],{"trials":567,"activeCount":75},[],{"trials":569,"activeCount":75},[570],{"nctId":571,"briefTitle":572,"status":81,"phases":573,"primaryCompletion":574,"completion":575,"start":576,"enrollment":577,"conditions":578,"interventions":580},"NCT02339038","Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia",[66],"2016-06-15","2018-07-13","2015-01-07",600,[579],"HCV HIV",[558],{"trials":582,"activeCount":75},[],{"intervention":584,"totalTrials":183,"cells":585},"kava",{"EARLY_PHASE1":586,"PHASE1":588,"PHASE2":590,"PHASE3":592,"PHASE4":594,"NA":603},{"trials":587,"activeCount":75},[],{"trials":589,"activeCount":75},[],{"trials":591,"activeCount":75},[],{"trials":593,"activeCount":75},[],{"trials":595,"activeCount":75},[596],{"nctId":597,"briefTitle":598,"status":81,"phases":599,"completion":526,"start":600,"enrollment":18,"conditions":601,"interventions":602},"NCT00009542","Effects of Kava on the Body's Elimination of Caffeine and Dextromethorphan",[66],"2001-01",[15],[584],{"trials":604,"activeCount":75},[],{"intervention":606,"totalTrials":183,"cells":607},"neostigmine",{"EARLY_PHASE1":608,"PHASE1":610,"PHASE2":612,"PHASE3":614,"PHASE4":616,"NA":628},{"trials":609,"activeCount":75},[],{"trials":611,"activeCount":75},[],{"trials":613,"activeCount":75},[],{"trials":615,"activeCount":75},[],{"trials":617,"activeCount":75},[618],{"nctId":619,"briefTitle":620,"status":81,"phases":621,"completion":622,"start":623,"enrollment":624,"conditions":625,"interventions":627},"NCT00001520","The Early Reversibility of Rocuronium After Different Doses of Neostigmine",[66],"2000-08","1996-09",60,[626],"Paralysis",[606],{"trials":629,"activeCount":75},[],{"intervention":631,"totalTrials":183,"cells":632},"Gingko Biloba",{"EARLY_PHASE1":633,"PHASE1":635,"PHASE2":637,"PHASE3":639,"PHASE4":641,"NA":655},{"trials":634,"activeCount":75},[],{"trials":636,"activeCount":75},[],{"trials":638,"activeCount":75},[],{"trials":640,"activeCount":75},[],{"trials":642,"activeCount":75},[643],{"nctId":644,"briefTitle":645,"status":81,"phases":646,"primaryCompletion":647,"completion":648,"start":649,"enrollment":650,"conditions":651,"interventions":652},"NCT00103012","Drug Interactions of Echinacea, Ginseng, and Ginkgo Biloba Taken With Lopinavir\u002FRitonavir in Healthy Volunteers",[66],"2011-01","2011-06","2005-01",47,[15],[631,653,654],"Echinacea purpurea","Panax ginseng",{"trials":656,"activeCount":75},[],{"intervention":653,"totalTrials":183,"cells":658},{"EARLY_PHASE1":659,"PHASE1":661,"PHASE2":663,"PHASE3":665,"PHASE4":667,"NA":673},{"trials":660,"activeCount":75},[],{"trials":662,"activeCount":75},[],{"trials":664,"activeCount":75},[],{"trials":666,"activeCount":75},[],{"trials":668,"activeCount":75},[669],{"nctId":644,"briefTitle":645,"status":81,"phases":670,"primaryCompletion":647,"completion":648,"start":649,"enrollment":650,"conditions":671,"interventions":672},[66],[15],[631,653,654],{"trials":674,"activeCount":75},[],{"intervention":654,"totalTrials":183,"cells":676},{"EARLY_PHASE1":677,"PHASE1":679,"PHASE2":681,"PHASE3":683,"PHASE4":685,"NA":691},{"trials":678,"activeCount":75},[],{"trials":680,"activeCount":75},[],{"trials":682,"activeCount":75},[],{"trials":684,"activeCount":75},[],{"trials":686,"activeCount":75},[687],{"nctId":644,"briefTitle":645,"status":81,"phases":688,"primaryCompletion":647,"completion":648,"start":649,"enrollment":650,"conditions":689,"interventions":690},[66],[15],[631,653,654],{"trials":692,"activeCount":75},[],{"intervention":694,"totalTrials":183,"cells":695},"Midazolam",{"EARLY_PHASE1":696,"PHASE1":698,"PHASE2":700,"PHASE3":702,"PHASE4":704,"NA":718},{"trials":697,"activeCount":75},[],{"trials":699,"activeCount":75},[],{"trials":701,"activeCount":75},[],{"trials":703,"activeCount":75},[],{"trials":705,"activeCount":75},[706],{"nctId":707,"briefTitle":708,"status":81,"phases":709,"primaryCompletion":710,"completion":710,"start":711,"enrollment":712,"conditions":713,"interventions":715},"NCT00050180","Influence of the MDR1 Genotype on Blood Levels of Indinavir and Saquinavir in Healthy Volunteers",[66],"2007-08-24","2002-11-22",81,[15,714],"HIV Infections",[694,716,717],"Indinavir","Saquinavir",{"trials":719,"activeCount":75},[],{"intervention":716,"totalTrials":183,"cells":721},{"EARLY_PHASE1":722,"PHASE1":724,"PHASE2":726,"PHASE3":728,"PHASE4":730,"NA":736},{"trials":723,"activeCount":75},[],{"trials":725,"activeCount":75},[],{"trials":727,"activeCount":75},[],{"trials":729,"activeCount":75},[],{"trials":731,"activeCount":75},[732],{"nctId":707,"briefTitle":708,"status":81,"phases":733,"primaryCompletion":710,"completion":710,"start":711,"enrollment":712,"conditions":734,"interventions":735},[66],[15,714],[694,716,717],{"trials":737,"activeCount":75},[],{"intervention":717,"totalTrials":183,"cells":739},{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":744,"PHASE3":746,"PHASE4":748,"NA":754},{"trials":741,"activeCount":75},[],{"trials":743,"activeCount":75},[],{"trials":745,"activeCount":75},[],{"trials":747,"activeCount":75},[],{"trials":749,"activeCount":75},[750],{"nctId":707,"briefTitle":708,"status":81,"phases":751,"primaryCompletion":710,"completion":710,"start":711,"enrollment":712,"conditions":752,"interventions":753},[66],[15,714],[694,716,717],{"trials":755,"activeCount":75},[],{"intervention":757,"totalTrials":183,"cells":758},"Zidovudine",{"EARLY_PHASE1":759,"PHASE1":761,"PHASE2":763,"PHASE3":765,"PHASE4":767,"NA":785},{"trials":760,"activeCount":75},[],{"trials":762,"activeCount":75},[],{"trials":764,"activeCount":75},[],{"trials":766,"activeCount":75},[],{"trials":768,"activeCount":75},[769],{"nctId":770,"briefTitle":771,"status":81,"phases":772,"primaryCompletion":773,"completion":774,"start":775,"enrollment":776,"conditions":777,"interventions":779},"NCT00342355","Antiretroviral Therapy for Advanced HIV Disease in South Africa",[66],"2008-03","2008-08","2004-01",1771,[778],"HIV",[757,780,781,782,783,784],"Stavudine","Didanosine","Lamivudine","Efavirenz","Lopinavir\u002FRitonavir",{"trials":786,"activeCount":75},[],{"intervention":780,"totalTrials":183,"cells":788},{"EARLY_PHASE1":789,"PHASE1":791,"PHASE2":793,"PHASE3":795,"PHASE4":797,"NA":803},{"trials":790,"activeCount":75},[],{"trials":792,"activeCount":75},[],{"trials":794,"activeCount":75},[],{"trials":796,"activeCount":75},[],{"trials":798,"activeCount":75},[799],{"nctId":770,"briefTitle":771,"status":81,"phases":800,"primaryCompletion":773,"completion":774,"start":775,"enrollment":776,"conditions":801,"interventions":802},[66],[778],[757,780,781,782,783,784],{"trials":804,"activeCount":75},[],{"intervention":781,"totalTrials":183,"cells":806},{"EARLY_PHASE1":807,"PHASE1":809,"PHASE2":811,"PHASE3":813,"PHASE4":815,"NA":821},{"trials":808,"activeCount":75},[],{"trials":810,"activeCount":75},[],{"trials":812,"activeCount":75},[],{"trials":814,"activeCount":75},[],{"trials":816,"activeCount":75},[817],{"nctId":770,"briefTitle":771,"status":81,"phases":818,"primaryCompletion":773,"completion":774,"start":775,"enrollment":776,"conditions":819,"interventions":820},[66],[778],[757,780,781,782,783,784],{"trials":822,"activeCount":75},[],{"intervention":782,"totalTrials":183,"cells":824},{"EARLY_PHASE1":825,"PHASE1":827,"PHASE2":829,"PHASE3":831,"PHASE4":833,"NA":839},{"trials":826,"activeCount":75},[],{"trials":828,"activeCount":75},[],{"trials":830,"activeCount":75},[],{"trials":832,"activeCount":75},[],{"trials":834,"activeCount":75},[835],{"nctId":770,"briefTitle":771,"status":81,"phases":836,"primaryCompletion":773,"completion":774,"start":775,"enrollment":776,"conditions":837,"interventions":838},[66],[778],[757,780,781,782,783,784],{"trials":840,"activeCount":75},[],{"intervention":783,"totalTrials":183,"cells":842},{"EARLY_PHASE1":843,"PHASE1":845,"PHASE2":847,"PHASE3":849,"PHASE4":851,"NA":857},{"trials":844,"activeCount":75},[],{"trials":846,"activeCount":75},[],{"trials":848,"activeCount":75},[],{"trials":850,"activeCount":75},[],{"trials":852,"activeCount":75},[853],{"nctId":770,"briefTitle":771,"status":81,"phases":854,"primaryCompletion":773,"completion":774,"start":775,"enrollment":776,"conditions":855,"interventions":856},[66],[778],[757,780,781,782,783,784],{"trials":858,"activeCount":75},[],{"intervention":860,"totalTrials":183,"cells":861},"Merrem",{"EARLY_PHASE1":862,"PHASE1":864,"PHASE2":866,"PHASE3":868,"PHASE4":870,"NA":881},{"trials":863,"activeCount":75},[],{"trials":865,"activeCount":75},[],{"trials":867,"activeCount":75},[],{"trials":869,"activeCount":75},[],{"trials":871,"activeCount":75},[872],{"nctId":873,"briefTitle":874,"status":81,"phases":875,"completion":876,"start":877,"enrollment":75,"conditions":878,"interventions":880},"NCT00410527","Effectiveness of Short-Course Versus Standard Antibiotic Therapy in ICU Patients",[66],"2007-05-22","2006-08-11",[879],"Bacterial Infections",[860],{"trials":882,"activeCount":75},[],{"intervention":884,"totalTrials":885,"cells":886},"melphalan",5,{"EARLY_PHASE1":887,"PHASE1":889,"PHASE2":891,"PHASE3":942,"PHASE4":954,"NA":956},{"trials":888,"activeCount":75},[],{"trials":890,"activeCount":75},[],{"trials":892,"activeCount":75},[893,907,921,935],{"nctId":894,"briefTitle":895,"status":81,"phases":896,"completion":897,"start":898,"enrollment":899,"conditions":900,"interventions":905},"NCT00019786","Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases",[64],"2006-01","1999-08",67,[901,902,23,903,904],"Colorectal Cancer","Islet Cell Tumor","Metastatic Cancer","Neuroendocrine Carcinoma",[906,884],"isolated perfusion",{"nctId":908,"briefTitle":909,"status":81,"phases":910,"completion":911,"start":898,"conditions":912,"interventions":919},"NCT00019968","Isolated Limb Perfusion of Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Soft Tissue Sarcoma of the Arm or Leg",[64],"2002-03",[913,914,915,916,917,918],"Stage IVB Adult Soft Tissue Sarcoma","Stage IIB Adult Soft Tissue Sarcoma","Stage IIC Adult Soft Tissue Sarcoma","Recurrent Adult Soft Tissue Sarcoma","Stage IVA Adult Soft Tissue Sarcoma","Stage III Adult Soft Tissue Sarcoma",[884,920],"tumor necrosis factor",{"nctId":922,"briefTitle":923,"status":81,"phases":924,"completion":911,"start":925,"conditions":926,"interventions":932},"NCT00019760","Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver",[64],"1999-04",[927,928,929,930,931],"Recurrent Colon Cancer","Liver Metastases","Stage IV Rectal Cancer","Recurrent Rectal Cancer","Stage IV Colon Cancer",[933,934,884],"floxuridine","leucovorin calcium",{"nctId":936,"briefTitle":937,"status":81,"phases":938,"primaryCompletion":939,"completion":773,"start":109,"enrollment":71,"conditions":940,"interventions":941},"NCT00089401","Isolated Hepatic Perfusion With Melphalan in Treating Patients With Unresectable Colorectal Cancer That Has Metastasized to the Liver",[64],"2006-11",[901,903],[906,884],{"trials":943,"activeCount":75},[944],{"nctId":945,"briefTitle":946,"status":81,"phases":947,"completion":649,"start":948,"conditions":949,"interventions":950},"NCT00020501","Chemotherapy With or Without Isolated Hepatic Perfusion With Melphalan in Treating Patients With Colorectal Cancer That Has Spread to the Liver",[65],"2001-03",[901,903],[951,933,952,953,934,884],"FOLFIRI regimen","fluorouracil","irinotecan hydrochloride",{"trials":955,"activeCount":75},[],{"trials":957,"activeCount":75},[],{"intervention":952,"totalTrials":156,"cells":959},{"EARLY_PHASE1":960,"PHASE1":962,"PHASE2":980,"PHASE3":993,"PHASE4":999,"NA":1001},{"trials":961,"activeCount":75},[],{"trials":963,"activeCount":75},[964],{"nctId":965,"briefTitle":966,"status":81,"phases":967,"completion":968,"start":969,"enrollment":970,"conditions":971,"interventions":978},"NCT00019513","Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas",[63],"2004-06","1998-08",108,[901,972,973,974,23,975,20,976,977,17],"Esophageal Cancer","Extrahepatic Bile Duct Cancer","Gallbladder Cancer","Lung Cancer","Pancreatic Cancer","Small Intestine Cancer",[952,979,934],"gemcitabine hydrochloride",{"trials":981,"activeCount":75},[982],{"nctId":983,"briefTitle":984,"status":81,"phases":985,"completion":911,"start":986,"conditions":987,"interventions":991},"NCT00020345","Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas",[64],"2000-09",[988,989,990],"Stage IVA Pancreatic Cancer","Stage III Pancreatic Cancer","Adenocarcinoma of the Pancreas",[952,992],"gemcitabine",{"trials":994,"activeCount":75},[995],{"nctId":945,"briefTitle":946,"status":81,"phases":996,"completion":649,"start":948,"conditions":997,"interventions":998},[65],[901,903],[951,933,952,953,934,884],{"trials":1000,"activeCount":75},[],{"trials":1002,"activeCount":75},[],{"intervention":97,"totalTrials":156,"cells":1004},{"EARLY_PHASE1":1005,"PHASE1":1007,"PHASE2":1013,"PHASE3":1019,"PHASE4":1025,"NA":1027},{"trials":1006,"activeCount":75},[],{"trials":1008,"activeCount":75},[1009],{"nctId":79,"briefTitle":80,"status":81,"phases":1010,"completion":83,"start":84,"enrollment":18,"conditions":1011,"interventions":1012},[63],[86,87,20,88,89,90],[70,92,93,94,95,96,97,98,99,100,101,102],{"trials":1014,"activeCount":75},[1015],{"nctId":398,"briefTitle":399,"status":81,"phases":1016,"completion":401,"start":402,"conditions":1017,"interventions":1018},[64],[87,20],[405,95,97,406,98,99,407,408,409,101,102],{"trials":1020,"activeCount":75},[1021],{"nctId":429,"briefTitle":430,"status":431,"phases":1022,"completion":433,"start":434,"enrollment":75,"conditions":1023,"interventions":1024},[65],[87],[405,95,97,406,408,409,101,437,102],{"trials":1026,"activeCount":75},[],{"trials":1028,"activeCount":75},[],{"intervention":101,"totalTrials":156,"cells":1030},{"EARLY_PHASE1":1031,"PHASE1":1033,"PHASE2":1039,"PHASE3":1045,"PHASE4":1051,"NA":1053},{"trials":1032,"activeCount":75},[],{"trials":1034,"activeCount":75},[1035],{"nctId":79,"briefTitle":80,"status":81,"phases":1036,"completion":83,"start":84,"enrollment":18,"conditions":1037,"interventions":1038},[63],[86,87,20,88,89,90],[70,92,93,94,95,96,97,98,99,100,101,102],{"trials":1040,"activeCount":75},[1041],{"nctId":398,"briefTitle":399,"status":81,"phases":1042,"completion":401,"start":402,"conditions":1043,"interventions":1044},[64],[87,20],[405,95,97,406,98,99,407,408,409,101,102],{"trials":1046,"activeCount":75},[1047],{"nctId":429,"briefTitle":430,"status":431,"phases":1048,"completion":433,"start":434,"enrollment":75,"conditions":1049,"interventions":1050},[65],[87],[405,95,97,406,408,409,101,437,102],{"trials":1052,"activeCount":75},[],{"trials":1054,"activeCount":75},[],{"intervention":102,"totalTrials":156,"cells":1056},{"EARLY_PHASE1":1057,"PHASE1":1059,"PHASE2":1065,"PHASE3":1071,"PHASE4":1077,"NA":1079},{"trials":1058,"activeCount":75},[],{"trials":1060,"activeCount":75},[1061],{"nctId":79,"briefTitle":80,"status":81,"phases":1062,"completion":83,"start":84,"enrollment":18,"conditions":1063,"interventions":1064},[63],[86,87,20,88,89,90],[70,92,93,94,95,96,97,98,99,100,101,102],{"trials":1066,"activeCount":75},[1067],{"nctId":398,"briefTitle":399,"status":81,"phases":1068,"completion":401,"start":402,"conditions":1069,"interventions":1070},[64],[87,20],[405,95,97,406,98,99,407,408,409,101,102],{"trials":1072,"activeCount":75},[1073],{"nctId":429,"briefTitle":430,"status":431,"phases":1074,"completion":433,"start":434,"enrollment":75,"conditions":1075,"interventions":1076},[65],[87],[405,95,97,406,408,409,101,437,102],{"trials":1078,"activeCount":75},[],{"trials":1080,"activeCount":75},[],{"intervention":934,"totalTrials":156,"cells":1082},{"EARLY_PHASE1":1083,"PHASE1":1085,"PHASE2":1091,"PHASE3":1097,"PHASE4":1103,"NA":1105},{"trials":1084,"activeCount":75},[],{"trials":1086,"activeCount":75},[1087],{"nctId":965,"briefTitle":966,"status":81,"phases":1088,"completion":968,"start":969,"enrollment":970,"conditions":1089,"interventions":1090},[63],[901,972,973,974,23,975,20,976,977,17],[952,979,934],{"trials":1092,"activeCount":75},[1093],{"nctId":922,"briefTitle":923,"status":81,"phases":1094,"completion":911,"start":925,"conditions":1095,"interventions":1096},[64],[927,928,929,930,931],[933,934,884],{"trials":1098,"activeCount":75},[1099],{"nctId":945,"briefTitle":946,"status":81,"phases":1100,"completion":649,"start":948,"conditions":1101,"interventions":1102},[65],[901,903],[951,933,952,953,934,884],{"trials":1104,"activeCount":75},[],{"trials":1106,"activeCount":75},[],{"intervention":405,"totalTrials":187,"cells":1108},{"EARLY_PHASE1":1109,"PHASE1":1111,"PHASE2":1113,"PHASE3":1119,"PHASE4":1125,"NA":1127},{"trials":1110,"activeCount":75},[],{"trials":1112,"activeCount":75},[],{"trials":1114,"activeCount":75},[1115],{"nctId":398,"briefTitle":399,"status":81,"phases":1116,"completion":401,"start":402,"conditions":1117,"interventions":1118},[64],[87,20],[405,95,97,406,98,99,407,408,409,101,102],{"trials":1120,"activeCount":75},[1121],{"nctId":429,"briefTitle":430,"status":431,"phases":1122,"completion":433,"start":434,"enrollment":75,"conditions":1123,"interventions":1124},[65],[87],[405,95,97,406,408,409,101,437,102],{"trials":1126,"activeCount":75},[],{"trials":1128,"activeCount":75},[],{"intervention":406,"totalTrials":187,"cells":1130},{"EARLY_PHASE1":1131,"PHASE1":1133,"PHASE2":1135,"PHASE3":1141,"PHASE4":1147,"NA":1149},{"trials":1132,"activeCount":75},[],{"trials":1134,"activeCount":75},[],{"trials":1136,"activeCount":75},[1137],{"nctId":398,"briefTitle":399,"status":81,"phases":1138,"completion":401,"start":402,"conditions":1139,"interventions":1140},[64],[87,20],[405,95,97,406,98,99,407,408,409,101,102],{"trials":1142,"activeCount":75},[1143],{"nctId":429,"briefTitle":430,"status":431,"phases":1144,"completion":433,"start":434,"enrollment":75,"conditions":1145,"interventions":1146},[65],[87],[405,95,97,406,408,409,101,437,102],{"trials":1148,"activeCount":75},[],{"trials":1150,"activeCount":75},[],{"intervention":408,"totalTrials":187,"cells":1152},{"EARLY_PHASE1":1153,"PHASE1":1155,"PHASE2":1157,"PHASE3":1163,"PHASE4":1169,"NA":1171},{"trials":1154,"activeCount":75},[],{"trials":1156,"activeCount":75},[],{"trials":1158,"activeCount":75},[1159],{"nctId":398,"briefTitle":399,"status":81,"phases":1160,"completion":401,"start":402,"conditions":1161,"interventions":1162},[64],[87,20],[405,95,97,406,98,99,407,408,409,101,102],{"trials":1164,"activeCount":75},[1165],{"nctId":429,"briefTitle":430,"status":431,"phases":1166,"completion":433,"start":434,"enrollment":75,"conditions":1167,"interventions":1168},[65],[87],[405,95,97,406,408,409,101,437,102],{"trials":1170,"activeCount":75},[],{"trials":1172,"activeCount":75},[],{"intervention":409,"totalTrials":187,"cells":1174},{"EARLY_PHASE1":1175,"PHASE1":1177,"PHASE2":1179,"PHASE3":1185,"PHASE4":1191,"NA":1193},{"trials":1176,"activeCount":75},[],{"trials":1178,"activeCount":75},[],{"trials":1180,"activeCount":75},[1181],{"nctId":398,"briefTitle":399,"status":81,"phases":1182,"completion":401,"start":402,"conditions":1183,"interventions":1184},[64],[87,20],[405,95,97,406,98,99,407,408,409,101,102],{"trials":1186,"activeCount":75},[1187],{"nctId":429,"briefTitle":430,"status":431,"phases":1188,"completion":433,"start":434,"enrollment":75,"conditions":1189,"interventions":1190},[65],[87],[405,95,97,406,408,409,101,437,102],{"trials":1192,"activeCount":75},[],{"trials":1194,"activeCount":75},[],{"intervention":933,"totalTrials":187,"cells":1196},{"EARLY_PHASE1":1197,"PHASE1":1199,"PHASE2":1201,"PHASE3":1207,"PHASE4":1213,"NA":1215},{"trials":1198,"activeCount":75},[],{"trials":1200,"activeCount":75},[],{"trials":1202,"activeCount":75},[1203],{"nctId":922,"briefTitle":923,"status":81,"phases":1204,"completion":911,"start":925,"conditions":1205,"interventions":1206},[64],[927,928,929,930,931],[933,934,884],{"trials":1208,"activeCount":75},[1209],{"nctId":945,"briefTitle":946,"status":81,"phases":1210,"completion":649,"start":948,"conditions":1211,"interventions":1212},[65],[901,903],[951,933,952,953,934,884],{"trials":1214,"activeCount":75},[],{"trials":1216,"activeCount":75},[],{"intervention":437,"totalTrials":183,"cells":1218},{"EARLY_PHASE1":1219,"PHASE1":1221,"PHASE2":1223,"PHASE3":1225,"PHASE4":1231,"NA":1233},{"trials":1220,"activeCount":75},[],{"trials":1222,"activeCount":75},[],{"trials":1224,"activeCount":75},[],{"trials":1226,"activeCount":75},[1227],{"nctId":429,"briefTitle":430,"status":431,"phases":1228,"completion":433,"start":434,"enrollment":75,"conditions":1229,"interventions":1230},[65],[87],[405,95,97,406,408,409,101,437,102],{"trials":1232,"activeCount":75},[],{"trials":1234,"activeCount":75},[],{"intervention":951,"totalTrials":183,"cells":1236},{"EARLY_PHASE1":1237,"PHASE1":1239,"PHASE2":1241,"PHASE3":1243,"PHASE4":1249,"NA":1251},{"trials":1238,"activeCount":75},[],{"trials":1240,"activeCount":75},[],{"trials":1242,"activeCount":75},[],{"trials":1244,"activeCount":75},[1245],{"nctId":945,"briefTitle":946,"status":81,"phases":1246,"completion":649,"start":948,"conditions":1247,"interventions":1248},[65],[901,903],[951,933,952,953,934,884],{"trials":1250,"activeCount":75},[],{"trials":1252,"activeCount":75},[],{"intervention":953,"totalTrials":183,"cells":1254},{"EARLY_PHASE1":1255,"PHASE1":1257,"PHASE2":1259,"PHASE3":1261,"PHASE4":1267,"NA":1269},{"trials":1256,"activeCount":75},[],{"trials":1258,"activeCount":75},[],{"trials":1260,"activeCount":75},[],{"trials":1262,"activeCount":75},[1263],{"nctId":945,"briefTitle":946,"status":81,"phases":1264,"completion":649,"start":948,"conditions":1265,"interventions":1266},[65],[901,903],[951,933,952,953,934,884],{"trials":1268,"activeCount":75},[],{"trials":1270,"activeCount":75},[],{"intervention":115,"totalTrials":885,"cells":1272},{"EARLY_PHASE1":1273,"PHASE1":1275,"PHASE2":1293,"PHASE3":1323,"PHASE4":1325,"NA":1327},{"trials":1274,"activeCount":75},[],{"trials":1276,"activeCount":75},[1277,1289],{"nctId":1278,"briefTitle":1279,"status":81,"phases":1280,"primaryCompletion":1281,"completion":1281,"start":1282,"enrollment":1283,"conditions":1284,"interventions":1286},"NCT00381875","Vaccine Therapy, Incomplete Freund's Adjuvant, and GM-CSF in Treating Patients With HIV",[63],"2011-02","2006-07",40,[1285],"Nonneoplastic Condition",[1287,115,1288],"E1M184V peptide vaccine","sargramostim",{"nctId":104,"briefTitle":105,"status":81,"phases":1290,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":1291,"interventions":1292},[63],[29],[113,114,70,115,116,117,95,100],{"trials":1294,"activeCount":75},[1295,1307,1311],{"nctId":1296,"briefTitle":1297,"status":81,"phases":1298,"primaryCompletion":1299,"completion":1300,"start":1301,"enrollment":1302,"conditions":1303,"interventions":1304},"NCT00077532","Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma",[64],"2007-01","2008-02","2004-03",179,[29],[1305,115,1306],"gp100 antigen","ipilimumab",{"nctId":162,"briefTitle":163,"status":81,"phases":1308,"primaryCompletion":165,"completion":123,"start":166,"enrollment":8,"conditions":1309,"interventions":1310},[63,64],[29],[114,70,115,169,117,95,100],{"nctId":1312,"briefTitle":1313,"status":81,"phases":1314,"primaryCompletion":1315,"completion":1316,"start":1317,"enrollment":1318,"conditions":1319,"interventions":1321},"NCT00295958","LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery",[64],"2006-06","2008-07","2005-12",26,[29,1320],"Non-melanomatous Skin Cancer",[460,1322,1305,115],"MART-1 antigen",{"trials":1324,"activeCount":75},[],{"trials":1326,"activeCount":75},[],{"trials":1328,"activeCount":75},[],{"intervention":1330,"totalTrials":1331,"cells":1332},"paclitaxel",4,{"EARLY_PHASE1":1333,"PHASE1":1335,"PHASE2":1365,"PHASE3":1375,"PHASE4":1377,"NA":1379},{"trials":1334,"activeCount":75},[],{"trials":1336,"activeCount":75},[1337,1347,1357],{"nctId":1338,"briefTitle":1339,"status":81,"phases":1340,"primaryCompletion":1282,"completion":1282,"start":1341,"enrollment":341,"conditions":1342,"interventions":1345},"NCT00019019","Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas",[63],"1994-10",[1343,26,33,975,20,29,1344,977,17],"Brain and Central Nervous System Tumors","Ovarian Cancer",[1346,1330],"carboxyamidotriazole",{"nctId":1348,"briefTitle":1349,"status":81,"phases":1350,"primaryCompletion":108,"completion":1351,"start":124,"enrollment":1352,"conditions":1353,"interventions":1355},"NCT00083057","Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck",[63],"2010-11",30,[1354],"Head and Neck Cancer",[1356,1330],"gefitinib",{"nctId":1358,"briefTitle":1359,"status":81,"phases":1360,"primaryCompletion":122,"completion":1361,"start":146,"conditions":1362,"interventions":1363},"NCT00095914","Paclitaxel and ABI-007 in Treating Patients With Locally Advanced or Metastatic Solid Tumors",[63],"2009-03",[17],[1330,1364],"paclitaxel albumin-stabilized nanoparticle formulation",{"trials":1366,"activeCount":75},[1367],{"nctId":1368,"briefTitle":1369,"status":81,"phases":1370,"completion":84,"start":898,"enrollment":1371,"conditions":1372,"interventions":1373},"NCT00019812","Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2",[64],55,[26],[1374,1330],"trastuzumab",{"trials":1376,"activeCount":75},[],{"trials":1378,"activeCount":75},[],{"trials":1380,"activeCount":75},[],{"intervention":117,"totalTrials":1331,"cells":1382},{"EARLY_PHASE1":1383,"PHASE1":1385,"PHASE2":1395,"PHASE3":1405,"PHASE4":1407,"NA":1409},{"trials":1384,"activeCount":75},[],{"trials":1386,"activeCount":75},[1387,1391],{"nctId":104,"briefTitle":105,"status":81,"phases":1388,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":1389,"interventions":1390},[63],[29],[113,114,70,115,116,117,95,100],{"nctId":119,"briefTitle":120,"status":81,"phases":1392,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":1393,"interventions":1394},[63],[29],[114,70,128,116,117,95,100],{"trials":1396,"activeCount":75},[1397,1401],{"nctId":142,"briefTitle":143,"status":81,"phases":1398,"primaryCompletion":145,"completion":145,"start":146,"enrollment":147,"conditions":1399,"interventions":1400},[64],[29],[114,70,117,95,100],{"nctId":162,"briefTitle":163,"status":81,"phases":1402,"primaryCompletion":165,"completion":123,"start":166,"enrollment":8,"conditions":1403,"interventions":1404},[63,64],[29],[114,70,115,169,117,95,100],{"trials":1406,"activeCount":75},[],{"trials":1408,"activeCount":75},[],{"trials":1410,"activeCount":75},[],{"intervention":1412,"totalTrials":156,"cells":1413},"thalidomide",{"EARLY_PHASE1":1414,"PHASE1":1416,"PHASE2":1418,"PHASE3":1449,"PHASE4":1451,"NA":1453},{"trials":1415,"activeCount":75},[],{"trials":1417,"activeCount":75},[],{"trials":1419,"activeCount":75},[1420,1432,1441],{"nctId":1421,"briefTitle":1422,"status":81,"phases":1423,"completion":1424,"start":1425,"conditions":1426,"interventions":1430},"NCT00020046","Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer",[64],"2003-09","1999-12",[1427,1428,1429],"Stage IV Prostate Cancer","Adenocarcinoma of the Prostate","Recurrent Prostate Cancer",[1431,1412],"docetaxel",{"nctId":1433,"briefTitle":1434,"status":81,"phases":1435,"primaryCompletion":1436,"completion":1436,"start":1301,"enrollment":624,"conditions":1437,"interventions":1439},"NCT00083005","Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate",[64],"2007-12",[1438],"Prostate Cancer",[1431,1440,1412],"estramustine phosphate sodium",{"nctId":1442,"briefTitle":1443,"status":134,"phases":1444,"primaryCompletion":1445,"completion":1445,"start":898,"enrollment":1446,"conditions":1447,"interventions":1448},"NCT00019747","Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer",[64],"2008-12",39,[901],[1412],{"trials":1450,"activeCount":75},[],{"trials":1452,"activeCount":75},[],{"trials":1454,"activeCount":75},[],{"intervention":1456,"totalTrials":156,"cells":1457},"carboplatin",{"EARLY_PHASE1":1458,"PHASE1":1460,"PHASE2":1475,"PHASE3":1496,"PHASE4":1498,"NA":1500},{"trials":1459,"activeCount":75},[],{"trials":1461,"activeCount":75},[1462],{"nctId":1463,"briefTitle":1464,"status":81,"phases":1465,"completion":1466,"start":1317,"enrollment":1318,"conditions":1467,"interventions":1472},"NCT00303940","Talabostat Combined With Temozolomide or Carboplatin in Treating Young Patients With Relapsed or Refractory Brain Tumors or Other Solid Tumors",[63],"2010-02",[1343,1468,33,23,1469,1344,1470,1471],"Childhood Germ Cell Tumor","Neuroblastoma","Sarcoma","Unspecified Childhood Solid Tumor, Protocol Specific",[1456,1473,1474],"talabostat mesylate","temozolomide",{"trials":1476,"activeCount":75},[1477,1487],{"nctId":1478,"briefTitle":1479,"status":81,"phases":1480,"primaryCompletion":1299,"completion":1481,"start":1482,"enrollment":1483,"conditions":1484,"interventions":1485},"NCT00352313","ATN-161 and Carboplatin in Treating Patients With Recurrent Malignant Glioma",[63,64],"2008-01","2006-05",82,[1343],[1486,1456],"ATN-161",{"nctId":1488,"briefTitle":1489,"status":81,"phases":1490,"completion":968,"start":433,"conditions":1491,"interventions":1493},"NCT00021047","Epirubicin, Carboplatin, and Capecitabine in Treating Patients With Unresectable Locally Advanced, Metastatic, or Recurrent Solid Tumor",[63,64],[972,973,1492,1354,23,17],"Gastric Cancer",[1494,1456,1495],"capecitabine","epirubicin hydrochloride",{"trials":1497,"activeCount":75},[],{"trials":1499,"activeCount":75},[],{"trials":1501,"activeCount":75},[],{"intervention":116,"totalTrials":156,"cells":1503},{"EARLY_PHASE1":1504,"PHASE1":1506,"PHASE2":1516,"PHASE3":1522,"PHASE4":1524,"NA":1526},{"trials":1505,"activeCount":75},[],{"trials":1507,"activeCount":75},[1508,1512],{"nctId":104,"briefTitle":105,"status":81,"phases":1509,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":1510,"interventions":1511},[63],[29],[113,114,70,115,116,117,95,100],{"nctId":119,"briefTitle":120,"status":81,"phases":1513,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":1514,"interventions":1515},[63],[29],[114,70,128,116,117,95,100],{"trials":1517,"activeCount":75},[1518],{"nctId":132,"briefTitle":133,"status":134,"phases":1519,"completion":136,"start":137,"enrollment":138,"conditions":1520,"interventions":1521},[64],[29],[114,70,116,95,100],{"trials":1523,"activeCount":75},[],{"trials":1525,"activeCount":75},[],{"trials":1527,"activeCount":75},[],{"intervention":98,"totalTrials":156,"cells":1529},{"EARLY_PHASE1":1530,"PHASE1":1532,"PHASE2":1547,"PHASE3":1553,"PHASE4":1555,"NA":1557},{"trials":1531,"activeCount":75},[],{"trials":1533,"activeCount":75},[1534,1538],{"nctId":79,"briefTitle":80,"status":81,"phases":1535,"completion":83,"start":84,"enrollment":18,"conditions":1536,"interventions":1537},[63],[86,87,20,88,89,90],[70,92,93,94,95,96,97,98,99,100,101,102],{"nctId":1539,"briefTitle":1540,"status":81,"phases":1541,"completion":1542,"start":1543,"conditions":1544,"interventions":1546},"NCT00020124","Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs",[63],"2002-12","2000-06",[975,1545,903],"Malignant Mesothelioma",[98],{"trials":1548,"activeCount":75},[1549],{"nctId":398,"briefTitle":399,"status":81,"phases":1550,"completion":401,"start":402,"conditions":1551,"interventions":1552},[64],[87,20],[405,95,97,406,98,99,407,408,409,101,102],{"trials":1554,"activeCount":75},[],{"trials":1556,"activeCount":75},[],{"trials":1558,"activeCount":75},[],{"intervention":1560,"totalTrials":156,"cells":1561},"L-NMMA",{"EARLY_PHASE1":1562,"PHASE1":1564,"PHASE2":1584,"PHASE3":1595,"PHASE4":1597,"NA":1599},{"trials":1563,"activeCount":75},[],{"trials":1565,"activeCount":75},[1566,1577],{"nctId":1567,"briefTitle":1568,"status":81,"phases":1569,"primaryCompletion":710,"completion":710,"start":1570,"enrollment":1571,"conditions":1572,"interventions":1574},"NCT00072826","Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease",[63],"2003-11-04",44,[1573],"Sickle Cell Disease",[1575,1560,1576],"Oxypurinol","Acetylcholine",{"nctId":1578,"briefTitle":1579,"status":81,"phases":1580,"completion":1581,"start":775,"enrollment":1352,"conditions":1582,"interventions":1583},"NCT00076414","The Effect of Lopinavir\u002FRitonavir on Endothelial Function",[63],"2005-09",[15],[1576,1560],{"trials":1585,"activeCount":75},[1586],{"nctId":1587,"briefTitle":1588,"status":81,"phases":1589,"completion":1590,"start":600,"enrollment":1591,"conditions":1592,"interventions":1594},"NCT00009581","Nitric Oxide to Improve Blood Flow in Sickle Cell Disease",[64],"2003-01",65,[1593],"Sickle Cell Anemia",[1560,1576],{"trials":1596,"activeCount":75},[],{"trials":1598,"activeCount":75},[],{"trials":1600,"activeCount":75},[],{"intervention":1576,"totalTrials":156,"cells":1602},{"EARLY_PHASE1":1603,"PHASE1":1605,"PHASE2":1615,"PHASE3":1621,"PHASE4":1623,"NA":1625},{"trials":1604,"activeCount":75},[],{"trials":1606,"activeCount":75},[1607,1611],{"nctId":1567,"briefTitle":1568,"status":81,"phases":1608,"primaryCompletion":710,"completion":710,"start":1570,"enrollment":1571,"conditions":1609,"interventions":1610},[63],[1573],[1575,1560,1576],{"nctId":1578,"briefTitle":1579,"status":81,"phases":1612,"completion":1581,"start":775,"enrollment":1352,"conditions":1613,"interventions":1614},[63],[15],[1576,1560],{"trials":1616,"activeCount":75},[1617],{"nctId":1587,"briefTitle":1588,"status":81,"phases":1618,"completion":1590,"start":600,"enrollment":1591,"conditions":1619,"interventions":1620},[64],[1593],[1560,1576],{"trials":1622,"activeCount":75},[],{"trials":1624,"activeCount":75},[],{"trials":1626,"activeCount":75},[],{"intervention":1306,"totalTrials":156,"cells":1628},{"EARLY_PHASE1":1629,"PHASE1":1631,"PHASE2":1642,"PHASE3":1656,"PHASE4":1658,"NA":1660},{"trials":1630,"activeCount":75},[],{"trials":1632,"activeCount":75},[1633],{"nctId":1634,"briefTitle":1635,"status":81,"phases":1636,"primaryCompletion":1637,"completion":1351,"start":1638,"enrollment":1639,"conditions":1640,"interventions":1641},"NCT00047164","Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy",[63],"2010-09","2002-09",89,[20],[1306],{"trials":1643,"activeCount":75},[1644,1648],{"nctId":1296,"briefTitle":1297,"status":81,"phases":1645,"primaryCompletion":1299,"completion":1300,"start":1301,"enrollment":1302,"conditions":1646,"interventions":1647},[64],[29],[1305,115,1306],{"nctId":1649,"briefTitle":1650,"status":81,"phases":1651,"primaryCompletion":1652,"completion":1300,"start":1653,"conditions":1654,"interventions":1655},"NCT00057889","Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer",[64],"2007-10","2003-02",[33],[1306],{"trials":1657,"activeCount":75},[],{"trials":1659,"activeCount":75},[],{"trials":1661,"activeCount":75},[],{"intervention":1431,"totalTrials":187,"cells":1663},{"EARLY_PHASE1":1664,"PHASE1":1666,"PHASE2":1668,"PHASE3":1678,"PHASE4":1680,"NA":1682},{"trials":1665,"activeCount":75},[],{"trials":1667,"activeCount":75},[],{"trials":1669,"activeCount":75},[1670,1674],{"nctId":1421,"briefTitle":1422,"status":81,"phases":1671,"completion":1424,"start":1425,"conditions":1672,"interventions":1673},[64],[1427,1428,1429],[1431,1412],{"nctId":1433,"briefTitle":1434,"status":81,"phases":1675,"primaryCompletion":1436,"completion":1436,"start":1301,"enrollment":624,"conditions":1676,"interventions":1677},[64],[1438],[1431,1440,1412],{"trials":1679,"activeCount":75},[],{"trials":1681,"activeCount":75},[],{"trials":1683,"activeCount":75},[],{"intervention":1474,"totalTrials":187,"cells":1685},{"EARLY_PHASE1":1686,"PHASE1":1688,"PHASE2":1694,"PHASE3":1707,"PHASE4":1709,"NA":1711},{"trials":1687,"activeCount":75},[],{"trials":1689,"activeCount":75},[1690],{"nctId":1463,"briefTitle":1464,"status":81,"phases":1691,"completion":1466,"start":1317,"enrollment":1318,"conditions":1692,"interventions":1693},[63],[1343,1468,33,23,1469,1344,1470,1471],[1456,1473,1474],{"trials":1695,"activeCount":75},[1696],{"nctId":1697,"briefTitle":1698,"status":81,"phases":1699,"primaryCompletion":1700,"completion":1700,"start":145,"enrollment":238,"conditions":1701,"interventions":1704},"NCT00826241","Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma",[64],"2018-07-31",[1702,1703],"Brain Tumors","Spinal Cord Tumors",[1705,1706],"Temozolomide","Lapatinib",{"trials":1708,"activeCount":75},[],{"trials":1710,"activeCount":75},[],{"trials":1712,"activeCount":75},[],{"intervention":906,"totalTrials":187,"cells":1714},{"EARLY_PHASE1":1715,"PHASE1":1717,"PHASE2":1719,"PHASE3":1729,"PHASE4":1731,"NA":1733},{"trials":1716,"activeCount":75},[],{"trials":1718,"activeCount":75},[],{"trials":1720,"activeCount":75},[1721,1725],{"nctId":894,"briefTitle":895,"status":81,"phases":1722,"completion":897,"start":898,"enrollment":899,"conditions":1723,"interventions":1724},[64],[901,902,23,903,904],[906,884],{"nctId":936,"briefTitle":937,"status":81,"phases":1726,"primaryCompletion":939,"completion":773,"start":109,"enrollment":71,"conditions":1727,"interventions":1728},[64],[901,903],[906,884],{"trials":1730,"activeCount":75},[],{"trials":1732,"activeCount":75},[],{"trials":1734,"activeCount":75},[],{"intervention":395,"totalTrials":187,"cells":1736},{"EARLY_PHASE1":1737,"PHASE1":1739,"PHASE2":1749,"PHASE3":1755,"PHASE4":1757,"NA":1759},{"trials":1738,"activeCount":75},[],{"trials":1740,"activeCount":75},[1741],{"nctId":1742,"briefTitle":1743,"status":81,"phases":1744,"primaryCompletion":1745,"completion":390,"start":1746,"conditions":1747,"interventions":1748},"NCT00031941","CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy",[63],"2007-09","2002-04",[20,977,17],[395],{"trials":1750,"activeCount":75},[1751],{"nctId":387,"briefTitle":388,"status":134,"phases":1752,"primaryCompletion":390,"completion":390,"start":136,"enrollment":27,"conditions":1753,"interventions":1754},[64],[392,393],[95,395,396],{"trials":1756,"activeCount":75},[],{"trials":1758,"activeCount":75},[],{"trials":1760,"activeCount":75},[],{"intervention":1374,"totalTrials":187,"cells":1762},{"EARLY_PHASE1":1763,"PHASE1":1765,"PHASE2":1767,"PHASE3":1781,"PHASE4":1783,"NA":1785},{"trials":1764,"activeCount":75},[],{"trials":1766,"activeCount":75},[],{"trials":1768,"activeCount":75},[1769,1777],{"nctId":1770,"briefTitle":1771,"status":81,"phases":1772,"completion":1652,"start":1317,"enrollment":1773,"conditions":1774,"interventions":1775},"NCT00301899","Trastuzumab and Pertuzumab in Treating Patients With Unresectable Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Trastuzumab",[64],37,[26],[1776,1374],"pertuzumab",{"nctId":1368,"briefTitle":1369,"status":81,"phases":1778,"completion":84,"start":898,"enrollment":1371,"conditions":1779,"interventions":1780},[64],[26],[1374,1330],{"trials":1782,"activeCount":75},[],{"trials":1784,"activeCount":75},[],{"trials":1786,"activeCount":75},[],{"intervention":96,"totalTrials":187,"cells":1788},{"EARLY_PHASE1":1789,"PHASE1":1791,"PHASE2":1797,"PHASE3":1811,"PHASE4":1813,"NA":1815},{"trials":1790,"activeCount":75},[],{"trials":1792,"activeCount":75},[1793],{"nctId":79,"briefTitle":80,"status":81,"phases":1794,"completion":83,"start":84,"enrollment":18,"conditions":1795,"interventions":1796},[63],[86,87,20,88,89,90],[70,92,93,94,95,96,97,98,99,100,101,102],{"trials":1798,"activeCount":75},[1799],{"nctId":1800,"briefTitle":1801,"status":81,"phases":1802,"completion":1803,"start":1804,"enrollment":1805,"conditions":1806,"interventions":1808},"NCT00001839","A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome",[64],"2000-05","1998-12",182,[1807,89],"Hematologic Diseases",[1809,1810],"Antithymocyte globulin","Cyclosporine",{"trials":1812,"activeCount":75},[],{"trials":1814,"activeCount":75},[],{"trials":1816,"activeCount":75},[],{"intervention":99,"totalTrials":187,"cells":1818},{"EARLY_PHASE1":1819,"PHASE1":1821,"PHASE2":1827,"PHASE3":1833,"PHASE4":1835,"NA":1837},{"trials":1820,"activeCount":75},[],{"trials":1822,"activeCount":75},[1823],{"nctId":79,"briefTitle":80,"status":81,"phases":1824,"completion":83,"start":84,"enrollment":18,"conditions":1825,"interventions":1826},[63],[86,87,20,88,89,90],[70,92,93,94,95,96,97,98,99,100,101,102],{"trials":1828,"activeCount":75},[1829],{"nctId":398,"briefTitle":399,"status":81,"phases":1830,"completion":401,"start":402,"conditions":1831,"interventions":1832},[64],[87,20],[405,95,97,406,98,99,407,408,409,101,102],{"trials":1834,"activeCount":75},[],{"trials":1836,"activeCount":75},[],{"trials":1838,"activeCount":75},[],{"intervention":1305,"totalTrials":187,"cells":1840},{"EARLY_PHASE1":1841,"PHASE1":1843,"PHASE2":1845,"PHASE3":1855,"PHASE4":1857,"NA":1859},{"trials":1842,"activeCount":75},[],{"trials":1844,"activeCount":75},[],{"trials":1846,"activeCount":75},[1847,1851],{"nctId":1296,"briefTitle":1297,"status":81,"phases":1848,"primaryCompletion":1299,"completion":1300,"start":1301,"enrollment":1302,"conditions":1849,"interventions":1850},[64],[29],[1305,115,1306],{"nctId":1312,"briefTitle":1313,"status":81,"phases":1852,"primaryCompletion":1315,"completion":1316,"start":1317,"enrollment":1318,"conditions":1853,"interventions":1854},[64],[29,1320],[460,1322,1305,115],{"trials":1856,"activeCount":75},[],{"trials":1858,"activeCount":75},[],{"trials":1860,"activeCount":75},[],{"intervention":1862,"totalTrials":183,"cells":1863},"Oral acamprosate",{"EARLY_PHASE1":1864,"PHASE1":1866,"PHASE2":1868,"PHASE3":1883,"PHASE4":1885,"NA":1887},{"trials":1865,"activeCount":75},[],{"trials":1867,"activeCount":75},[],{"trials":1869,"activeCount":75},[1870],{"nctId":1871,"briefTitle":1872,"status":81,"phases":1873,"primaryCompletion":1874,"completion":1874,"start":1875,"enrollment":1876,"conditions":1877,"interventions":1882},"NCT00106106","Acamprosate to Reduce Symptoms of Alcohol Withdrawal",[64],"2010-07","2005-03",56,[1878,1879,1880,1881],"Alcohol-Related Disorders","Alcohol Dependence","Alcoholism","Healthy Volunteer",[1862],{"trials":1884,"activeCount":75},[],{"trials":1886,"activeCount":75},[],{"trials":1888,"activeCount":75},[],{"intervention":992,"totalTrials":183,"cells":1890},{"EARLY_PHASE1":1891,"PHASE1":1893,"PHASE2":1895,"PHASE3":1901,"PHASE4":1903,"NA":1905},{"trials":1892,"activeCount":75},[],{"trials":1894,"activeCount":75},[],{"trials":1896,"activeCount":75},[1897],{"nctId":983,"briefTitle":984,"status":81,"phases":1898,"completion":911,"start":986,"conditions":1899,"interventions":1900},[64],[988,989,990],[952,992],{"trials":1902,"activeCount":75},[],{"trials":1904,"activeCount":75},[],{"trials":1906,"activeCount":75},[],{"intervention":381,"totalTrials":183,"cells":1908},{"EARLY_PHASE1":1909,"PHASE1":1911,"PHASE2":1913,"PHASE3":1919,"PHASE4":1921,"NA":1923},{"trials":1910,"activeCount":75},[],{"trials":1912,"activeCount":75},[],{"trials":1914,"activeCount":75},[1915],{"nctId":373,"briefTitle":374,"status":134,"phases":1916,"primaryCompletion":376,"completion":376,"start":108,"enrollment":147,"conditions":1917,"interventions":1918},[63,64],[378,379],[269,268,381],{"trials":1920,"activeCount":75},[],{"trials":1922,"activeCount":75},[],{"trials":1924,"activeCount":75},[],{"intervention":1926,"totalTrials":183,"cells":1927},"talampanel",{"EARLY_PHASE1":1928,"PHASE1":1930,"PHASE2":1932,"PHASE3":1940,"PHASE4":1942,"NA":1944},{"trials":1929,"activeCount":75},[],{"trials":1931,"activeCount":75},[],{"trials":1933,"activeCount":75},[1934],{"nctId":1935,"briefTitle":1936,"status":81,"phases":1937,"completion":165,"start":166,"conditions":1938,"interventions":1939},"NCT00064363","Talampanel in Treating Patients With Recurrent High-Grade Glioma",[64],[1343],[1926],{"trials":1941,"activeCount":75},[],{"trials":1943,"activeCount":75},[],{"trials":1945,"activeCount":75},[],{"intervention":1947,"totalTrials":183,"cells":1948},"Lepirudin",{"EARLY_PHASE1":1949,"PHASE1":1951,"PHASE2":1953,"PHASE3":1965,"PHASE4":1967,"NA":1969},{"trials":1950,"activeCount":75},[],{"trials":1952,"activeCount":75},[],{"trials":1954,"activeCount":75},[1955],{"nctId":1956,"briefTitle":1957,"status":81,"phases":1958,"completion":1959,"start":1960,"enrollment":1961,"conditions":1962,"interventions":1964},"NCT00039767","Heparin Versus Lepirudin Flushes in Preventing Blockage of Venous Access Devices",[64],"2006-04","2002-05",340,[1963],"Thrombosis",[1947],{"trials":1966,"activeCount":75},[],{"trials":1968,"activeCount":75},[],{"trials":1970,"activeCount":75},[],{"intervention":1972,"totalTrials":183,"cells":1973},"Daclizumab",{"EARLY_PHASE1":1974,"PHASE1":1976,"PHASE2":1978,"PHASE3":1990,"PHASE4":1992,"NA":1994},{"trials":1975,"activeCount":75},[],{"trials":1977,"activeCount":75},[],{"trials":1979,"activeCount":75},[1980],{"nctId":1981,"briefTitle":1982,"status":81,"phases":1983,"completion":1984,"start":1985,"enrollment":1986,"conditions":1987,"interventions":1989},"NCT00049725","Daclizumab to Treat Chronic Immune Thrombocytopenia",[64],"2004-12","2002-11",24,[1988],"Thrombocytopenia",[1972],{"trials":1991,"activeCount":75},[],{"trials":1993,"activeCount":75},[],{"trials":1995,"activeCount":75},[],{"intervention":1997,"totalTrials":183,"cells":1998},"Platelet Transfusion - LONG Platelet Transfusion",{"EARLY_PHASE1":1999,"PHASE1":2001,"PHASE2":2003,"PHASE3":2015,"PHASE4":2017,"NA":2019},{"trials":2000,"activeCount":75},[],{"trials":2002,"activeCount":75},[],{"trials":2004,"activeCount":75},[2005],{"nctId":2006,"briefTitle":2007,"status":134,"phases":2008,"primaryCompletion":2009,"completion":2009,"start":2010,"enrollment":187,"conditions":2011,"interventions":2013},"NCT03712618","The SOLID Platelet Study",[64],"2021-07-31","2019-06-10",[2012,1988],"Platelet Transfusion Refractoriness (PTR)",[1997,2014],"Platelet Transfusion - SHORT Platelet Transfusion",{"trials":2016,"activeCount":75},[],{"trials":2018,"activeCount":75},[],{"trials":2020,"activeCount":75},[],{"intervention":2014,"totalTrials":183,"cells":2022},{"EARLY_PHASE1":2023,"PHASE1":2025,"PHASE2":2027,"PHASE3":2033,"PHASE4":2035,"NA":2037},{"trials":2024,"activeCount":75},[],{"trials":2026,"activeCount":75},[],{"trials":2028,"activeCount":75},[2029],{"nctId":2006,"briefTitle":2007,"status":134,"phases":2030,"primaryCompletion":2009,"completion":2009,"start":2010,"enrollment":187,"conditions":2031,"interventions":2032},[64],[2012,1988],[1997,2014],{"trials":2034,"activeCount":75},[],{"trials":2036,"activeCount":75},[],{"trials":2038,"activeCount":75},[],{"intervention":1776,"totalTrials":183,"cells":2040},{"EARLY_PHASE1":2041,"PHASE1":2043,"PHASE2":2045,"PHASE3":2051,"PHASE4":2053,"NA":2055},{"trials":2042,"activeCount":75},[],{"trials":2044,"activeCount":75},[],{"trials":2046,"activeCount":75},[2047],{"nctId":1770,"briefTitle":1771,"status":81,"phases":2048,"completion":1652,"start":1317,"enrollment":1773,"conditions":2049,"interventions":2050},[64],[26],[1776,1374],{"trials":2052,"activeCount":75},[],{"trials":2054,"activeCount":75},[],{"trials":2056,"activeCount":75},[],{"intervention":920,"totalTrials":183,"cells":2058},{"EARLY_PHASE1":2059,"PHASE1":2061,"PHASE2":2063,"PHASE3":2069,"PHASE4":2071,"NA":2073},{"trials":2060,"activeCount":75},[],{"trials":2062,"activeCount":75},[],{"trials":2064,"activeCount":75},[2065],{"nctId":908,"briefTitle":909,"status":81,"phases":2066,"completion":911,"start":898,"conditions":2067,"interventions":2068},[64],[913,914,915,916,917,918],[884,920],{"trials":2070,"activeCount":75},[],{"trials":2072,"activeCount":75},[],{"trials":2074,"activeCount":75},[],{"intervention":2076,"totalTrials":183,"cells":2077},"[18F] FMISO",{"EARLY_PHASE1":2078,"PHASE1":2080,"PHASE2":2082,"PHASE3":2095,"PHASE4":2097,"NA":2099},{"trials":2079,"activeCount":75},[],{"trials":2081,"activeCount":75},[],{"trials":2083,"activeCount":75},[2084],{"nctId":2085,"briefTitle":2086,"status":81,"phases":2087,"primaryCompletion":2088,"completion":2088,"start":2089,"enrollment":156,"conditions":2090,"interventions":2094},"NCT02471313","Integrated Imaging Strategy to Phenotype Progression of Liver Tumors During and After Chemoembolization",[64],"2018-03-07","2015-06-12",[23,2091,2092,2093],"Liver Neoplasm","Hepatocellular Carcinoma","HCC",[2076],{"trials":2096,"activeCount":75},[],{"trials":2098,"activeCount":75},[],{"trials":2100,"activeCount":75},[],{"intervention":2102,"totalTrials":183,"cells":2103},"Synthetic Human Parathyroid Hormone 1-34 pump",{"EARLY_PHASE1":2104,"PHASE1":2106,"PHASE2":2108,"PHASE3":2123,"PHASE4":2125,"NA":2127},{"trials":2105,"activeCount":75},[],{"trials":2107,"activeCount":75},[],{"trials":2109,"activeCount":75},[2110],{"nctId":2111,"briefTitle":2112,"status":81,"phases":2113,"primaryCompletion":2114,"completion":2114,"start":2115,"enrollment":2116,"conditions":2117,"interventions":2122},"NCT00743782","Comparing Pump With Subcutaneous Injection Delivery of PTH 1-34 in the Management of Chronic Hypoparathyroidism",[64],"2014-04-07","2008-08-22",21,[2118,2119,2120,2121],"Hypoparathyroidism","Hypocalcemia","Autoimmune Polyendocrine Syndrome Type 1","Autosomal Dominant Hypocalcemia Type 1 (ADH1)",[2102],{"trials":2124,"activeCount":75},[],{"trials":2126,"activeCount":75},[],{"trials":2128,"activeCount":75},[],{"intervention":1809,"totalTrials":183,"cells":2130},{"EARLY_PHASE1":2131,"PHASE1":2133,"PHASE2":2135,"PHASE3":2141,"PHASE4":2143,"NA":2145},{"trials":2132,"activeCount":75},[],{"trials":2134,"activeCount":75},[],{"trials":2136,"activeCount":75},[2137],{"nctId":1800,"briefTitle":1801,"status":81,"phases":2138,"completion":1803,"start":1804,"enrollment":1805,"conditions":2139,"interventions":2140},[64],[1807,89],[1809,1810],{"trials":2142,"activeCount":75},[],{"trials":2144,"activeCount":75},[],{"trials":2146,"activeCount":75},[],{"intervention":2148,"totalTrials":183,"cells":2149},"Ponatinib",{"EARLY_PHASE1":2150,"PHASE1":2152,"PHASE2":2154,"PHASE3":2166,"PHASE4":2168,"NA":2170},{"trials":2151,"activeCount":75},[],{"trials":2153,"activeCount":75},[],{"trials":2155,"activeCount":75},[2156],{"nctId":2157,"briefTitle":2158,"status":134,"phases":2159,"primaryCompletion":2160,"completion":2161,"start":2162,"enrollment":156,"conditions":2163,"interventions":2165},"NCT01838642","Ponatinib for Advanced Medullary Thyroid Cancer",[64],"2015-12","2016-01","2013-03",[2164],"Thyroid Neoplasms",[2148],{"trials":2167,"activeCount":75},[],{"trials":2169,"activeCount":75},[],{"trials":2171,"activeCount":75},[],{"intervention":2173,"totalTrials":183,"cells":2174},"OT-551 antioxidant eye drop",{"EARLY_PHASE1":2175,"PHASE1":2177,"PHASE2":2179,"PHASE3":2192,"PHASE4":2194,"NA":2196},{"trials":2176,"activeCount":75},[],{"trials":2178,"activeCount":75},[],{"trials":2180,"activeCount":75},[2181],{"nctId":2182,"briefTitle":2183,"status":81,"phases":2184,"primaryCompletion":2185,"completion":2185,"start":2186,"enrollment":11,"conditions":2187,"interventions":2191},"NCT00306488","OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration",[64],"2010-03","2006-03",[2188,2189,2190],"Geographic Atrophy","Age-Related Macular Degeneration","AMD",[2173],{"trials":2193,"activeCount":75},[],{"trials":2195,"activeCount":75},[],{"trials":2197,"activeCount":75},[],{"intervention":396,"totalTrials":183,"cells":2199},{"EARLY_PHASE1":2200,"PHASE1":2202,"PHASE2":2204,"PHASE3":2210,"PHASE4":2212,"NA":2214},{"trials":2201,"activeCount":75},[],{"trials":2203,"activeCount":75},[],{"trials":2205,"activeCount":75},[2206],{"nctId":387,"briefTitle":388,"status":134,"phases":2207,"primaryCompletion":390,"completion":390,"start":136,"enrollment":27,"conditions":2208,"interventions":2209},[64],[392,393],[95,395,396],{"trials":2211,"activeCount":75},[],{"trials":2213,"activeCount":75},[],{"trials":2215,"activeCount":75},[],{"intervention":407,"totalTrials":183,"cells":2217},{"EARLY_PHASE1":2218,"PHASE1":2220,"PHASE2":2222,"PHASE3":2228,"PHASE4":2230,"NA":2232},{"trials":2219,"activeCount":75},[],{"trials":2221,"activeCount":75},[],{"trials":2223,"activeCount":75},[2224],{"nctId":398,"briefTitle":399,"status":81,"phases":2225,"completion":401,"start":402,"conditions":2226,"interventions":2227},[64],[87,20],[405,95,97,406,98,99,407,408,409,101,102],{"trials":2229,"activeCount":75},[],{"trials":2231,"activeCount":75},[],{"trials":2233,"activeCount":75},[],{"intervention":1486,"totalTrials":183,"cells":2235},{"EARLY_PHASE1":2236,"PHASE1":2238,"PHASE2":2240,"PHASE3":2246,"PHASE4":2248,"NA":2250},{"trials":2237,"activeCount":75},[],{"trials":2239,"activeCount":75},[],{"trials":2241,"activeCount":75},[2242],{"nctId":1478,"briefTitle":1479,"status":81,"phases":2243,"primaryCompletion":1299,"completion":1481,"start":1482,"enrollment":1483,"conditions":2244,"interventions":2245},[63,64],[1343],[1486,1456],{"trials":2247,"activeCount":75},[],{"trials":2249,"activeCount":75},[],{"trials":2251,"activeCount":75},[],{"intervention":2253,"totalTrials":183,"cells":2254},"Microplasmin",{"EARLY_PHASE1":2255,"PHASE1":2257,"PHASE2":2259,"PHASE3":2269,"PHASE4":2271,"NA":2273},{"trials":2256,"activeCount":75},[],{"trials":2258,"activeCount":75},[],{"trials":2260,"activeCount":75},[2261],{"nctId":2262,"briefTitle":2263,"status":134,"phases":2264,"primaryCompletion":2265,"completion":2265,"start":647,"enrollment":187,"conditions":2266,"interventions":2268},"NCT01194674","Microplasmin Intravitreal Administration in Participants With Uveitic Macular Edema",[63,64],"2011-12",[2267],"Uveitis",[2253],{"trials":2270,"activeCount":75},[],{"trials":2272,"activeCount":75},[],{"trials":2274,"activeCount":75},[],{"intervention":1440,"totalTrials":183,"cells":2276},{"EARLY_PHASE1":2277,"PHASE1":2279,"PHASE2":2281,"PHASE3":2287,"PHASE4":2289,"NA":2291},{"trials":2278,"activeCount":75},[],{"trials":2280,"activeCount":75},[],{"trials":2282,"activeCount":75},[2283],{"nctId":1433,"briefTitle":1434,"status":81,"phases":2284,"primaryCompletion":1436,"completion":1436,"start":1301,"enrollment":624,"conditions":2285,"interventions":2286},[64],[1438],[1431,1440,1412],{"trials":2288,"activeCount":75},[],{"trials":2290,"activeCount":75},[],{"trials":2292,"activeCount":75},[],{"intervention":1706,"totalTrials":183,"cells":2294},{"EARLY_PHASE1":2295,"PHASE1":2297,"PHASE2":2299,"PHASE3":2305,"PHASE4":2307,"NA":2309},{"trials":2296,"activeCount":75},[],{"trials":2298,"activeCount":75},[],{"trials":2300,"activeCount":75},[2301],{"nctId":1697,"briefTitle":1698,"status":81,"phases":2302,"primaryCompletion":1700,"completion":1700,"start":145,"enrollment":238,"conditions":2303,"interventions":2304},[64],[1702,1703],[1705,1706],{"trials":2306,"activeCount":75},[],{"trials":2308,"activeCount":75},[],{"trials":2310,"activeCount":75},[],{"intervention":2312,"totalTrials":183,"cells":2313},"Leucovorin",{"EARLY_PHASE1":2314,"PHASE1":2316,"PHASE2":2318,"PHASE3":2330,"PHASE4":2332,"NA":2334},{"trials":2315,"activeCount":75},[],{"trials":2317,"activeCount":75},[],{"trials":2319,"activeCount":75},[2320],{"nctId":2321,"briefTitle":2322,"status":81,"phases":2323,"completion":2324,"start":2325,"enrollment":352,"conditions":2326,"interventions":2329},"NCT00004997","Leucovorin for the Treatment of 5 q Minus Syndrome",[64],"2002-07","1998-04",[2327,2328],"5q Minus Syndrome","Myelodysplastic Syndrome",[2312],{"trials":2331,"activeCount":75},[],{"trials":2333,"activeCount":75},[],{"trials":2335,"activeCount":75},[],{"intervention":2337,"totalTrials":183,"cells":2338},"Asunaprevir and Daclatasvir",{"EARLY_PHASE1":2339,"PHASE1":2341,"PHASE2":2343,"PHASE3":2356,"PHASE4":2358,"NA":2360},{"trials":2340,"activeCount":75},[],{"trials":2342,"activeCount":75},[],{"trials":2344,"activeCount":75},[2345],{"nctId":2346,"briefTitle":2347,"status":81,"phases":2348,"primaryCompletion":2349,"completion":2350,"start":2351,"enrollment":1352,"conditions":2352,"interventions":2354},"NCT02124044","Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCV",[64],"2016-03","2016-11","2014-02",[2353],"HIV-HCV",[2337,2355],"Asunaprevir and Daclatasvir with BMS-791325",{"trials":2357,"activeCount":75},[],{"trials":2359,"activeCount":75},[],{"trials":2361,"activeCount":75},[],{"intervention":2355,"totalTrials":183,"cells":2363},{"EARLY_PHASE1":2364,"PHASE1":2366,"PHASE2":2368,"PHASE3":2374,"PHASE4":2376,"NA":2378},{"trials":2365,"activeCount":75},[],{"trials":2367,"activeCount":75},[],{"trials":2369,"activeCount":75},[2370],{"nctId":2346,"briefTitle":2347,"status":81,"phases":2371,"primaryCompletion":2349,"completion":2350,"start":2351,"enrollment":1352,"conditions":2372,"interventions":2373},[64],[2353],[2337,2355],{"trials":2375,"activeCount":75},[],{"trials":2377,"activeCount":75},[],{"trials":2379,"activeCount":75},[],{"intervention":1494,"totalTrials":183,"cells":2381},{"EARLY_PHASE1":2382,"PHASE1":2384,"PHASE2":2386,"PHASE3":2392,"PHASE4":2394,"NA":2396},{"trials":2383,"activeCount":75},[],{"trials":2385,"activeCount":75},[],{"trials":2387,"activeCount":75},[2388],{"nctId":1488,"briefTitle":1489,"status":81,"phases":2389,"completion":968,"start":433,"conditions":2390,"interventions":2391},[63,64],[972,973,1492,1354,23,17],[1494,1456,1495],{"trials":2393,"activeCount":75},[],{"trials":2395,"activeCount":75},[],{"trials":2397,"activeCount":75},[],{"intervention":1495,"totalTrials":183,"cells":2399},{"EARLY_PHASE1":2400,"PHASE1":2402,"PHASE2":2404,"PHASE3":2410,"PHASE4":2412,"NA":2414},{"trials":2401,"activeCount":75},[],{"trials":2403,"activeCount":75},[],{"trials":2405,"activeCount":75},[2406],{"nctId":1488,"briefTitle":1489,"status":81,"phases":2407,"completion":968,"start":433,"conditions":2408,"interventions":2409},[63,64],[972,973,1492,1354,23,17],[1494,1456,1495],{"trials":2411,"activeCount":75},[],{"trials":2413,"activeCount":75},[],{"trials":2415,"activeCount":75},[],{"intervention":2417,"totalTrials":183,"cells":2418},"[18F]-CP18",{"EARLY_PHASE1":2419,"PHASE1":2421,"PHASE2":2423,"PHASE3":2436,"PHASE4":2438,"NA":2440},{"trials":2420,"activeCount":75},[],{"trials":2422,"activeCount":75},[],{"trials":2424,"activeCount":75},[2425],{"nctId":2426,"briefTitle":2427,"status":431,"phases":2428,"primaryCompletion":2429,"completion":2429,"start":2430,"enrollment":75,"conditions":2431,"interventions":2435},"NCT01766622","18F-CP18 Imaging Studies for Cancer Treatment With Birinapant",[64],"2013-07-24","2012-11-30",[2432,1344,2433,2434],"Ovarian Neoplasms","Fallopian Tube Neoplasms","Fallopian Tube Cancer",[2417],{"trials":2437,"activeCount":75},[],{"trials":2439,"activeCount":75},[],{"trials":2441,"activeCount":75},[],{"intervention":2443,"totalTrials":183,"cells":2444},"tanespimycin",{"EARLY_PHASE1":2445,"PHASE1":2447,"PHASE2":2449,"PHASE3":2458,"PHASE4":2460,"NA":2462},{"trials":2446,"activeCount":75},[],{"trials":2448,"activeCount":75},[],{"trials":2450,"activeCount":75},[2451],{"nctId":2452,"briefTitle":2453,"status":81,"phases":2454,"primaryCompletion":1436,"completion":155,"start":1482,"enrollment":1773,"conditions":2455,"interventions":2457},"NCT00132015","17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis",[64],[86,87,20,1285,2456],"Precancerous Condition",[2443],{"trials":2459,"activeCount":75},[],{"trials":2461,"activeCount":75},[],{"trials":2463,"activeCount":75},[],{"intervention":159,"totalTrials":183,"cells":2465},{"EARLY_PHASE1":2466,"PHASE1":2468,"PHASE2":2470,"PHASE3":2476,"PHASE4":2478,"NA":2480},{"trials":2467,"activeCount":75},[],{"trials":2469,"activeCount":75},[],{"trials":2471,"activeCount":75},[2472],{"nctId":151,"briefTitle":152,"status":134,"phases":2473,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":2474,"interventions":2475},[64],[33,29,17],[114,159,160,70,95,100],{"trials":2477,"activeCount":75},[],{"trials":2479,"activeCount":75},[],{"trials":2481,"activeCount":75},[],{"intervention":160,"totalTrials":183,"cells":2483},{"EARLY_PHASE1":2484,"PHASE1":2486,"PHASE2":2488,"PHASE3":2494,"PHASE4":2496,"NA":2498},{"trials":2485,"activeCount":75},[],{"trials":2487,"activeCount":75},[],{"trials":2489,"activeCount":75},[2490],{"nctId":151,"briefTitle":152,"status":134,"phases":2491,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":2492,"interventions":2493},[64],[33,29,17],[114,159,160,70,95,100],{"trials":2495,"activeCount":75},[],{"trials":2497,"activeCount":75},[],{"trials":2499,"activeCount":75},[],{"intervention":2501,"totalTrials":183,"cells":2502},"Hydrocortisone",{"EARLY_PHASE1":2503,"PHASE1":2505,"PHASE2":2507,"PHASE3":2520,"PHASE4":2522,"NA":2524},{"trials":2504,"activeCount":75},[],{"trials":2506,"activeCount":75},[],{"trials":2508,"activeCount":75},[2509],{"nctId":2510,"briefTitle":2511,"status":81,"phases":2512,"primaryCompletion":2513,"completion":2513,"start":2514,"enrollment":71,"conditions":2515,"interventions":2519},"NCT01859312","Comparison of Cortisol Pump With Standard Treatment for Congenital Adrenal Hyperplasia",[64],"2016-12-02","2013-05-06",[2516,2517,2518],"Adrenal Insufficiency","Excess Androgen","Congenital Adrenal Hyperplasia (CAH)",[2501],{"trials":2521,"activeCount":75},[],{"trials":2523,"activeCount":75},[],{"trials":2525,"activeCount":75},[],{"intervention":2527,"totalTrials":183,"cells":2528},"Nitric Oxide",{"EARLY_PHASE1":2529,"PHASE1":2531,"PHASE2":2533,"PHASE3":2545,"PHASE4":2547,"NA":2549},{"trials":2530,"activeCount":75},[],{"trials":2532,"activeCount":75},[],{"trials":2534,"activeCount":75},[2535],{"nctId":2536,"briefTitle":2537,"status":81,"phases":2538,"completion":2539,"start":2540,"enrollment":238,"conditions":2541,"interventions":2543},"NCT00001716","Effects of Nitric Oxide and Nitroglycerin in Patients With Sickle Cell Anemia",[64],"2003-07","1998-07",[2542,1593],"Chest Pain",[2527,2544],"Nitroglycerin",{"trials":2546,"activeCount":75},[],{"trials":2548,"activeCount":75},[],{"trials":2550,"activeCount":75},[],{"intervention":2544,"totalTrials":183,"cells":2552},{"EARLY_PHASE1":2553,"PHASE1":2555,"PHASE2":2557,"PHASE3":2563,"PHASE4":2565,"NA":2567},{"trials":2554,"activeCount":75},[],{"trials":2556,"activeCount":75},[],{"trials":2558,"activeCount":75},[2559],{"nctId":2536,"briefTitle":2537,"status":81,"phases":2560,"completion":2539,"start":2540,"enrollment":238,"conditions":2561,"interventions":2562},[64],[2542,1593],[2527,2544],{"trials":2564,"activeCount":75},[],{"trials":2566,"activeCount":75},[],{"trials":2568,"activeCount":75},[],{"intervention":169,"totalTrials":183,"cells":2570},{"EARLY_PHASE1":2571,"PHASE1":2573,"PHASE2":2575,"PHASE3":2581,"PHASE4":2583,"NA":2585},{"trials":2572,"activeCount":75},[],{"trials":2574,"activeCount":75},[],{"trials":2576,"activeCount":75},[2577],{"nctId":162,"briefTitle":163,"status":81,"phases":2578,"primaryCompletion":165,"completion":123,"start":166,"enrollment":8,"conditions":2579,"interventions":2580},[63,64],[29],[114,70,115,169,117,95,100],{"trials":2582,"activeCount":75},[],{"trials":2584,"activeCount":75},[],{"trials":2586,"activeCount":75},[],{"intervention":1322,"totalTrials":183,"cells":2588},{"EARLY_PHASE1":2589,"PHASE1":2591,"PHASE2":2593,"PHASE3":2599,"PHASE4":2601,"NA":2603},{"trials":2590,"activeCount":75},[],{"trials":2592,"activeCount":75},[],{"trials":2594,"activeCount":75},[2595],{"nctId":1312,"briefTitle":1313,"status":81,"phases":2596,"primaryCompletion":1315,"completion":1316,"start":1317,"enrollment":1318,"conditions":2597,"interventions":2598},[64],[29,1320],[460,1322,1305,115],{"trials":2600,"activeCount":75},[],{"trials":2602,"activeCount":75},[],{"trials":2604,"activeCount":75},[],{"intervention":2606,"totalTrials":183,"cells":2607},"ravuconazole",{"EARLY_PHASE1":2608,"PHASE1":2610,"PHASE2":2612,"PHASE3":2623,"PHASE4":2625,"NA":2627},{"trials":2609,"activeCount":75},[],{"trials":2611,"activeCount":75},[],{"trials":2613,"activeCount":75},[2614],{"nctId":2615,"briefTitle":2616,"status":81,"phases":2617,"completion":146,"start":166,"conditions":2618,"interventions":2622},"NCT00064311","Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation",[63,64],[26,86,2619,2620,87,20,88,89,90,1469,1344,2621],"Gestational Trophoblastic Tumor","Infection","Testicular Germ Cell Tumor",[2606],{"trials":2624,"activeCount":75},[],{"trials":2626,"activeCount":75},[],{"trials":2628,"activeCount":75},[],{"intervention":2630,"totalTrials":183,"cells":2631},"Omr-IgG-am",{"EARLY_PHASE1":2632,"PHASE1":2634,"PHASE2":2636,"PHASE3":2647,"PHASE4":2649,"NA":2651},{"trials":2633,"activeCount":75},[],{"trials":2635,"activeCount":75},[],{"trials":2637,"activeCount":75},[2638],{"nctId":2639,"briefTitle":2640,"status":81,"phases":2641,"primaryCompletion":2642,"completion":2642,"start":2643,"enrollment":187,"conditions":2644,"interventions":2646},"NCT00069316","Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease",[64],"2007-06-27","2003-09-22",[2645],"West Nile Virus",[2630],{"trials":2648,"activeCount":75},[],{"trials":2650,"activeCount":75},[],{"trials":2652,"activeCount":75},[],{"intervention":2654,"totalTrials":183,"cells":2655},"Nitazoxanide With Pegylated Interferon And Ribavirin",{"EARLY_PHASE1":2656,"PHASE1":2658,"PHASE2":2660,"PHASE3":2671,"PHASE4":2673,"NA":2675},{"trials":2657,"activeCount":75},[],{"trials":2659,"activeCount":75},[],{"trials":2661,"activeCount":75},[2662],{"nctId":2663,"briefTitle":2664,"status":81,"phases":2665,"primaryCompletion":2666,"completion":2666,"start":107,"enrollment":71,"conditions":2667,"interventions":2670},"NCT01185028","A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures",[63,64],"2011-10",[2668,2669],"Hepatitis C Infection","HIV Infection",[2654],{"trials":2672,"activeCount":75},[],{"trials":2674,"activeCount":75},[],{"trials":2676,"activeCount":75},[],{"intervention":2678,"totalTrials":156,"cells":2679},"Ritonavir",{"EARLY_PHASE1":2680,"PHASE1":2682,"PHASE2":2718,"PHASE3":2720,"PHASE4":2722,"NA":2724},{"trials":2681,"activeCount":75},[],{"trials":2683,"activeCount":75},[2684,2697,2706],{"nctId":2685,"briefTitle":2686,"status":81,"phases":2687,"primaryCompletion":2688,"completion":2688,"start":2689,"enrollment":2690,"conditions":2691,"interventions":2696},"NCT01148004","The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers",[63],"2013-07-29","2010-05-13",25,[778,2692,2693,2694,2695],"Fenofibrate","Protease Inhibitors","Hypertriglyceridemia","Glucuronosyltransferase",[2692,2678,784],{"nctId":2698,"briefTitle":2699,"status":81,"phases":2700,"primaryCompletion":2701,"completion":2701,"start":2702,"enrollment":1283,"conditions":2703,"interventions":2704},"NCT01896622","The Interaction of Two HIV Medications With Blood Clot Medications in Healthy Volunteers",[63],"2017-01-17","2013-06-18",[778],[2678,2705],"Cobicistat",{"nctId":2707,"briefTitle":2708,"status":81,"phases":2709,"primaryCompletion":2710,"completion":2710,"start":2711,"enrollment":2712,"conditions":2713,"interventions":2715},"NCT00936793","Drug Interaction Study Between Inhaled Beclomethasone and Protease Inhibitors in Healthy Volunteers",[63],"2011-06-10","2009-07-06",53,[778,2714],"Asthma",[2716,2678,2717],"Darunavir","Beclomethasone Dipropionate HFA",{"trials":2719,"activeCount":75},[],{"trials":2721,"activeCount":75},[],{"trials":2723,"activeCount":75},[],{"trials":2725,"activeCount":75},[],{"intervention":2727,"totalTrials":187,"cells":2728},"darunavir\u002Fcobicistat",{"EARLY_PHASE1":2729,"PHASE1":2731,"PHASE2":2754,"PHASE3":2756,"PHASE4":2758,"NA":2760},{"trials":2730,"activeCount":75},[],{"trials":2732,"activeCount":75},[2733,2744],{"nctId":2734,"briefTitle":2735,"status":81,"phases":2736,"primaryCompletion":2737,"completion":2737,"start":2738,"enrollment":1773,"conditions":2739,"interventions":2741},"NCT02771249","Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers",[63],"2021-08-17","2016-06-03",[2740],"HIV Infected Population With Latent Tuberculosis",[2742,2727,2743],"rifapentene","Isoniazid",{"nctId":2745,"briefTitle":2746,"status":81,"phases":2747,"primaryCompletion":2748,"completion":2748,"start":2749,"enrollment":27,"conditions":2750,"interventions":2751},"NCT03864406","Impact of Steady State Cobicistat and Darunavir\u002FCobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers",[63],"2022-12-10","2019-06-04",[31],[2705,2752,2753],"Darunavir\u002FCobicistat","Rivaroxaban",{"trials":2755,"activeCount":75},[],{"trials":2757,"activeCount":75},[],{"trials":2759,"activeCount":75},[],{"trials":2761,"activeCount":75},[],{"intervention":2743,"totalTrials":187,"cells":2763},{"EARLY_PHASE1":2764,"PHASE1":2766,"PHASE2":2784,"PHASE3":2786,"PHASE4":2788,"NA":2790},{"trials":2765,"activeCount":75},[],{"trials":2767,"activeCount":75},[2768,2772],{"nctId":2734,"briefTitle":2735,"status":81,"phases":2769,"primaryCompletion":2737,"completion":2737,"start":2738,"enrollment":1773,"conditions":2770,"interventions":2771},[63],[2740],[2742,2727,2743],{"nctId":2773,"briefTitle":2774,"status":81,"phases":2775,"primaryCompletion":2776,"completion":2777,"start":2778,"enrollment":2779,"conditions":2780,"interventions":2781},"NCT03510468","Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)",[63],"2022-11-15","2022-12-21","2018-06-12",51,[31],[2782,2783,2743],"Tenofovir alafenamide","Rifapentine",{"trials":2785,"activeCount":75},[],{"trials":2787,"activeCount":75},[],{"trials":2789,"activeCount":75},[],{"trials":2791,"activeCount":75},[],{"intervention":2705,"totalTrials":187,"cells":2793},{"EARLY_PHASE1":2794,"PHASE1":2796,"PHASE2":2806,"PHASE3":2808,"PHASE4":2810,"NA":2812},{"trials":2795,"activeCount":75},[],{"trials":2797,"activeCount":75},[2798,2802],{"nctId":2745,"briefTitle":2746,"status":81,"phases":2799,"primaryCompletion":2748,"completion":2748,"start":2749,"enrollment":27,"conditions":2800,"interventions":2801},[63],[31],[2705,2752,2753],{"nctId":2698,"briefTitle":2699,"status":81,"phases":2803,"primaryCompletion":2701,"completion":2701,"start":2702,"enrollment":1283,"conditions":2804,"interventions":2805},[63],[778],[2678,2705],{"trials":2807,"activeCount":75},[],{"trials":2809,"activeCount":75},[],{"trials":2811,"activeCount":75},[],{"trials":2813,"activeCount":75},[],{"intervention":2815,"totalTrials":187,"cells":2816},"colloidal gold-bound tumor necrosis factor",{"EARLY_PHASE1":2817,"PHASE1":2828,"PHASE2":2837,"PHASE3":2839,"PHASE4":2841,"NA":2843},{"trials":2818,"activeCount":75},[2819],{"nctId":2820,"briefTitle":2821,"status":81,"phases":2822,"completion":154,"start":2823,"enrollment":970,"conditions":2824,"interventions":2827},"NCT00436410","Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer",[62],"2006-12",[2825,26,901,2826,33,23,29,1344,976,1470],"Adrenocortical Carcinoma","Gastrointestinal Cancer",[2815],{"trials":2829,"activeCount":75},[2830],{"nctId":2831,"briefTitle":2832,"status":81,"phases":2833,"primaryCompletion":2834,"completion":390,"start":1482,"enrollment":624,"conditions":2835,"interventions":2836},"NCT00356980","TNF-Bound Colloidal Gold in Treating Patients With Advanced Solid Tumors",[63],"2009-02",[17],[2815],{"trials":2838,"activeCount":75},[],{"trials":2840,"activeCount":75},[],{"trials":2842,"activeCount":75},[],{"trials":2844,"activeCount":75},[],{"intervention":2692,"totalTrials":183,"cells":2846},{"EARLY_PHASE1":2847,"PHASE1":2849,"PHASE2":2855,"PHASE3":2857,"PHASE4":2859,"NA":2861},{"trials":2848,"activeCount":75},[],{"trials":2850,"activeCount":75},[2851],{"nctId":2685,"briefTitle":2686,"status":81,"phases":2852,"primaryCompletion":2688,"completion":2688,"start":2689,"enrollment":2690,"conditions":2853,"interventions":2854},[63],[778,2692,2693,2694,2695],[2692,2678,784],{"trials":2856,"activeCount":75},[],{"trials":2858,"activeCount":75},[],{"trials":2860,"activeCount":75},[],{"trials":2862,"activeCount":75},[],{"intervention":1346,"totalTrials":183,"cells":2864},{"EARLY_PHASE1":2865,"PHASE1":2867,"PHASE2":2873,"PHASE3":2875,"PHASE4":2877,"NA":2879},{"trials":2866,"activeCount":75},[],{"trials":2868,"activeCount":75},[2869],{"nctId":1338,"briefTitle":1339,"status":81,"phases":2870,"primaryCompletion":1282,"completion":1282,"start":1341,"enrollment":341,"conditions":2871,"interventions":2872},[63],[1343,26,33,975,20,29,1344,977,17],[1346,1330],{"trials":2874,"activeCount":75},[],{"trials":2876,"activeCount":75},[],{"trials":2878,"activeCount":75},[],{"trials":2880,"activeCount":75},[],{"intervention":2882,"totalTrials":183,"cells":2883},"Cell Transfer",{"EARLY_PHASE1":2884,"PHASE1":2886,"PHASE2":2896,"PHASE3":2898,"PHASE4":2900,"NA":2902},{"trials":2885,"activeCount":75},[],{"trials":2887,"activeCount":75},[2888],{"nctId":2889,"briefTitle":2890,"status":134,"phases":2891,"primaryCompletion":2892,"completion":2892,"start":2893,"enrollment":352,"conditions":2894,"interventions":2895},"NCT00559416","Lymphocyte Infusions for the Treatment of HIV-Infected Patients Failing Anti-HIV Therapy",[63],"2016-09-30","2007-11-08",[714],[2882],{"trials":2897,"activeCount":75},[],{"trials":2899,"activeCount":75},[],{"trials":2901,"activeCount":75},[],{"trials":2903,"activeCount":75},[],{"intervention":2905,"totalTrials":183,"cells":2906},"alvespimycin hydrochloride",{"EARLY_PHASE1":2907,"PHASE1":2909,"PHASE2":2917,"PHASE3":2919,"PHASE4":2921,"NA":2923},{"trials":2908,"activeCount":75},[],{"trials":2910,"activeCount":75},[2911],{"nctId":2912,"briefTitle":2913,"status":81,"phases":2914,"primaryCompletion":2185,"completion":83,"start":968,"enrollment":1283,"conditions":2915,"interventions":2916},"NCT00088868","17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma",[63],[20,977,17],[2905],{"trials":2918,"activeCount":75},[],{"trials":2920,"activeCount":75},[],{"trials":2922,"activeCount":75},[],{"trials":2924,"activeCount":75},[],{"intervention":2742,"totalTrials":183,"cells":2926},{"EARLY_PHASE1":2927,"PHASE1":2929,"PHASE2":2935,"PHASE3":2937,"PHASE4":2939,"NA":2941},{"trials":2928,"activeCount":75},[],{"trials":2930,"activeCount":75},[2931],{"nctId":2734,"briefTitle":2735,"status":81,"phases":2932,"primaryCompletion":2737,"completion":2737,"start":2738,"enrollment":1773,"conditions":2933,"interventions":2934},[63],[2740],[2742,2727,2743],{"trials":2936,"activeCount":75},[],{"trials":2938,"activeCount":75},[],{"trials":2940,"activeCount":75},[],{"trials":2942,"activeCount":75},[],{"intervention":2944,"totalTrials":183,"cells":2945},"Silymarin",{"EARLY_PHASE1":2946,"PHASE1":2948,"PHASE2":2958,"PHASE3":2960,"PHASE4":2962,"NA":2964},{"trials":2947,"activeCount":75},[],{"trials":2949,"activeCount":75},[2950],{"nctId":2951,"briefTitle":2952,"status":81,"phases":2953,"completion":2954,"start":2955,"enrollment":18,"conditions":2956,"interventions":2957},"NCT00011635","The Effect of Milk Thistle on the Pharmacokinetics of Indinavir",[63],"2001-06","2001-02",[2669,15],[2944],{"trials":2959,"activeCount":75},[],{"trials":2961,"activeCount":75},[],{"trials":2963,"activeCount":75},[],{"trials":2965,"activeCount":75},[],{"intervention":2967,"totalTrials":183,"cells":2968},"EBV-LMP-2",{"EARLY_PHASE1":2969,"PHASE1":2971,"PHASE2":2981,"PHASE3":2983,"PHASE4":2985,"NA":2987},{"trials":2970,"activeCount":75},[],{"trials":2972,"activeCount":75},[2973],{"nctId":2974,"briefTitle":2975,"status":81,"phases":2976,"completion":1482,"start":84,"enrollment":2977,"conditions":2978,"interventions":2980},"NCT00078494","Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer",[63],99,[2979],"Nasopharyngeal Neoplasms",[2967],{"trials":2982,"activeCount":75},[],{"trials":2984,"activeCount":75},[],{"trials":2986,"activeCount":75},[],{"trials":2988,"activeCount":75},[],{"intervention":1473,"totalTrials":183,"cells":2990},{"EARLY_PHASE1":2991,"PHASE1":2993,"PHASE2":2999,"PHASE3":3001,"PHASE4":3003,"NA":3005},{"trials":2992,"activeCount":75},[],{"trials":2994,"activeCount":75},[2995],{"nctId":1463,"briefTitle":1464,"status":81,"phases":2996,"completion":1466,"start":1317,"enrollment":1318,"conditions":2997,"interventions":2998},[63],[1343,1468,33,23,1469,1344,1470,1471],[1456,1473,1474],{"trials":3000,"activeCount":75},[],{"trials":3002,"activeCount":75},[],{"trials":3004,"activeCount":75},[],{"trials":3006,"activeCount":75},[],{"intervention":3008,"totalTrials":183,"cells":3009},"Mycophenolic Acid",{"EARLY_PHASE1":3010,"PHASE1":3012,"PHASE2":3022,"PHASE3":3024,"PHASE4":3026,"NA":3028},{"trials":3011,"activeCount":75},[],{"trials":3013,"activeCount":75},[3014],{"nctId":3015,"briefTitle":3016,"status":81,"phases":3017,"completion":1482,"start":137,"enrollment":3018,"conditions":3019,"interventions":3020},"NCT00128947","Pharmacokinetics of Mycophenolate Mofetil in Healthy Volunteers",[63],130,[15],[3008,3021],"Mycophenolate 7-O-Phenolic Glucuronide",{"trials":3023,"activeCount":75},[],{"trials":3025,"activeCount":75},[],{"trials":3027,"activeCount":75},[],{"trials":3029,"activeCount":75},[],{"intervention":3021,"totalTrials":183,"cells":3031},{"EARLY_PHASE1":3032,"PHASE1":3034,"PHASE2":3040,"PHASE3":3042,"PHASE4":3044,"NA":3046},{"trials":3033,"activeCount":75},[],{"trials":3035,"activeCount":75},[3036],{"nctId":3015,"briefTitle":3016,"status":81,"phases":3037,"completion":1482,"start":137,"enrollment":3018,"conditions":3038,"interventions":3039},[63],[15],[3008,3021],{"trials":3041,"activeCount":75},[],{"trials":3043,"activeCount":75},[],{"trials":3045,"activeCount":75},[],{"trials":3047,"activeCount":75},[],{"intervention":3049,"totalTrials":183,"cells":3050},"Reference Endotoxin",{"EARLY_PHASE1":3051,"PHASE1":3053,"PHASE2":3069,"PHASE3":3071,"PHASE4":3073,"NA":3075},{"trials":3052,"activeCount":75},[],{"trials":3054,"activeCount":75},[3055],{"nctId":3056,"briefTitle":3057,"status":81,"phases":3058,"primaryCompletion":3059,"completion":3060,"start":3061,"enrollment":3062,"conditions":3063,"interventions":3067},"NCT00001303","Effects of Endotoxin in Normal Human Volunteers",[63],"2007-03-21","2018-05-17","1992-04-06",198,[15,3064,3065,3066],"Lung Disease","Sepsis","Septic Shock",[3049,3068],"Inhaled Nitric Oxide",{"trials":3070,"activeCount":75},[],{"trials":3072,"activeCount":75},[],{"trials":3074,"activeCount":75},[],{"trials":3076,"activeCount":75},[],{"intervention":3068,"totalTrials":183,"cells":3078},{"EARLY_PHASE1":3079,"PHASE1":3081,"PHASE2":3087,"PHASE3":3089,"PHASE4":3091,"NA":3093},{"trials":3080,"activeCount":75},[],{"trials":3082,"activeCount":75},[3083],{"nctId":3056,"briefTitle":3057,"status":81,"phases":3084,"primaryCompletion":3059,"completion":3060,"start":3061,"enrollment":3062,"conditions":3085,"interventions":3086},[63],[15,3064,3065,3066],[3049,3068],{"trials":3088,"activeCount":75},[],{"trials":3090,"activeCount":75},[],{"trials":3092,"activeCount":75},[],{"trials":3094,"activeCount":75},[],{"intervention":1287,"totalTrials":183,"cells":3096},{"EARLY_PHASE1":3097,"PHASE1":3099,"PHASE2":3105,"PHASE3":3107,"PHASE4":3109,"NA":3111},{"trials":3098,"activeCount":75},[],{"trials":3100,"activeCount":75},[3101],{"nctId":1278,"briefTitle":1279,"status":81,"phases":3102,"primaryCompletion":1281,"completion":1281,"start":1282,"enrollment":1283,"conditions":3103,"interventions":3104},[63],[1285],[1287,115,1288],{"trials":3106,"activeCount":75},[],{"trials":3108,"activeCount":75},[],{"trials":3110,"activeCount":75},[],{"trials":3112,"activeCount":75},[],{"intervention":1288,"totalTrials":183,"cells":3114},{"EARLY_PHASE1":3115,"PHASE1":3117,"PHASE2":3123,"PHASE3":3125,"PHASE4":3127,"NA":3129},{"trials":3116,"activeCount":75},[],{"trials":3118,"activeCount":75},[3119],{"nctId":1278,"briefTitle":1279,"status":81,"phases":3120,"primaryCompletion":1281,"completion":1281,"start":1282,"enrollment":1283,"conditions":3121,"interventions":3122},[63],[1285],[1287,115,1288],{"trials":3124,"activeCount":75},[],{"trials":3126,"activeCount":75},[],{"trials":3128,"activeCount":75},[],{"trials":3130,"activeCount":75},[],{"intervention":3132,"totalTrials":183,"cells":3133},"Pravastatin",{"EARLY_PHASE1":3134,"PHASE1":3136,"PHASE2":3148,"PHASE3":3150,"PHASE4":3152,"NA":3154},{"trials":3135,"activeCount":75},[],{"trials":3137,"activeCount":75},[3138],{"nctId":3139,"briefTitle":3140,"status":81,"phases":3141,"completion":3142,"start":1960,"enrollment":3143,"conditions":3144,"interventions":3145},"NCT00039663","Endothelial Dysfunction as a Risk Factor in HIV Study",[63],"2005-10",75,[714],[3132,3146,3147],"Gemfibrozil","Rosiglitazone",{"trials":3149,"activeCount":75},[],{"trials":3151,"activeCount":75},[],{"trials":3153,"activeCount":75},[],{"trials":3155,"activeCount":75},[],{"intervention":3147,"totalTrials":183,"cells":3157},{"EARLY_PHASE1":3158,"PHASE1":3160,"PHASE2":3166,"PHASE3":3168,"PHASE4":3170,"NA":3172},{"trials":3159,"activeCount":75},[],{"trials":3161,"activeCount":75},[3162],{"nctId":3139,"briefTitle":3140,"status":81,"phases":3163,"completion":3142,"start":1960,"enrollment":3143,"conditions":3164,"interventions":3165},[63],[714],[3132,3146,3147],{"trials":3167,"activeCount":75},[],{"trials":3169,"activeCount":75},[],{"trials":3171,"activeCount":75},[],{"trials":3173,"activeCount":75},[],{"intervention":3175,"totalTrials":183,"cells":3176},"entinostat",{"EARLY_PHASE1":3177,"PHASE1":3179,"PHASE2":3190,"PHASE3":3192,"PHASE4":3194,"NA":3196},{"trials":3178,"activeCount":75},[],{"trials":3180,"activeCount":75},[3181],{"nctId":3182,"briefTitle":3183,"status":81,"phases":3184,"primaryCompletion":3185,"completion":3186,"start":948,"enrollment":3143,"conditions":3187,"interventions":3189},"NCT00020579","MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma",[63],"2008-04","2008-10",[3188],"Cancer",[3175],{"trials":3191,"activeCount":75},[],{"trials":3193,"activeCount":75},[],{"trials":3195,"activeCount":75},[],{"trials":3197,"activeCount":75},[],{"intervention":2753,"totalTrials":183,"cells":3199},{"EARLY_PHASE1":3200,"PHASE1":3202,"PHASE2":3208,"PHASE3":3210,"PHASE4":3212,"NA":3214},{"trials":3201,"activeCount":75},[],{"trials":3203,"activeCount":75},[3204],{"nctId":2745,"briefTitle":2746,"status":81,"phases":3205,"primaryCompletion":2748,"completion":2748,"start":2749,"enrollment":27,"conditions":3206,"interventions":3207},[63],[31],[2705,2752,2753],{"trials":3209,"activeCount":75},[],{"trials":3211,"activeCount":75},[],{"trials":3213,"activeCount":75},[],{"trials":3215,"activeCount":75},[],{"intervention":3217,"totalTrials":183,"cells":3218},"lyso-thermosensitive liposomal doxorubicin",{"EARLY_PHASE1":3219,"PHASE1":3221,"PHASE2":3230,"PHASE3":3232,"PHASE4":3234,"NA":3236},{"trials":3220,"activeCount":75},[],{"trials":3222,"activeCount":75},[3223],{"nctId":3224,"briefTitle":3225,"status":81,"phases":3226,"completion":3227,"start":146,"enrollment":1352,"conditions":3228,"interventions":3229},"NCT00093444","Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors",[63],"2010-01",[23,903],[3217],{"trials":3231,"activeCount":75},[],{"trials":3233,"activeCount":75},[],{"trials":3235,"activeCount":75},[],{"trials":3237,"activeCount":75},[],{"intervention":3239,"totalTrials":183,"cells":3240},"Hydroxyurea",{"EARLY_PHASE1":3241,"PHASE1":3243,"PHASE2":3255,"PHASE3":3257,"PHASE4":3259,"NA":3261},{"trials":3242,"activeCount":75},[],{"trials":3244,"activeCount":75},[3245],{"nctId":3246,"briefTitle":3247,"status":81,"phases":3248,"primaryCompletion":3249,"completion":3249,"start":3250,"enrollment":1446,"conditions":3251,"interventions":3252},"NCT00056433","Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia",[63],"2006-12-27","2003-03-10",[1593],[3239,3253,3254],"L-Arginine","Sildenafil",{"trials":3256,"activeCount":75},[],{"trials":3258,"activeCount":75},[],{"trials":3260,"activeCount":75},[],{"trials":3262,"activeCount":75},[],{"intervention":3253,"totalTrials":183,"cells":3264},{"EARLY_PHASE1":3265,"PHASE1":3267,"PHASE2":3273,"PHASE3":3275,"PHASE4":3277,"NA":3279},{"trials":3266,"activeCount":75},[],{"trials":3268,"activeCount":75},[3269],{"nctId":3246,"briefTitle":3247,"status":81,"phases":3270,"primaryCompletion":3249,"completion":3249,"start":3250,"enrollment":1446,"conditions":3271,"interventions":3272},[63],[1593],[3239,3253,3254],{"trials":3274,"activeCount":75},[],{"trials":3276,"activeCount":75},[],{"trials":3278,"activeCount":75},[],{"trials":3280,"activeCount":75},[],{"intervention":3254,"totalTrials":183,"cells":3282},{"EARLY_PHASE1":3283,"PHASE1":3285,"PHASE2":3291,"PHASE3":3293,"PHASE4":3295,"NA":3297},{"trials":3284,"activeCount":75},[],{"trials":3286,"activeCount":75},[3287],{"nctId":3246,"briefTitle":3247,"status":81,"phases":3288,"primaryCompletion":3249,"completion":3249,"start":3250,"enrollment":1446,"conditions":3289,"interventions":3290},[63],[1593],[3239,3253,3254],{"trials":3292,"activeCount":75},[],{"trials":3294,"activeCount":75},[],{"trials":3296,"activeCount":75},[],{"trials":3298,"activeCount":75},[],{"intervention":3300,"totalTrials":183,"cells":3301},"Budesonide",{"EARLY_PHASE1":3302,"PHASE1":3304,"PHASE2":3321,"PHASE3":3323,"PHASE4":3325,"NA":3327},{"trials":3303,"activeCount":75},[],{"trials":3305,"activeCount":75},[3306],{"nctId":3307,"briefTitle":3308,"status":134,"phases":3309,"primaryCompletion":3310,"completion":3311,"start":3312,"enrollment":3313,"conditions":3314,"interventions":3317},"NCT01950507","Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease",[63],"2018-05-10","2020-02-26","2014-02-20",15,[3315,3316],"Stem Cell Transplantation","Graft vs Host Disease",[3300,3318,3319,3320],"Fluconazole","Voriconazole","Micafungin",{"trials":3322,"activeCount":75},[],{"trials":3324,"activeCount":75},[],{"trials":3326,"activeCount":75},[],{"trials":3328,"activeCount":75},[],{"intervention":3318,"totalTrials":183,"cells":3330},{"EARLY_PHASE1":3331,"PHASE1":3333,"PHASE2":3339,"PHASE3":3341,"PHASE4":3343,"NA":3345},{"trials":3332,"activeCount":75},[],{"trials":3334,"activeCount":75},[3335],{"nctId":3307,"briefTitle":3308,"status":134,"phases":3336,"primaryCompletion":3310,"completion":3311,"start":3312,"enrollment":3313,"conditions":3337,"interventions":3338},[63],[3315,3316],[3300,3318,3319,3320],{"trials":3340,"activeCount":75},[],{"trials":3342,"activeCount":75},[],{"trials":3344,"activeCount":75},[],{"trials":3346,"activeCount":75},[],{"intervention":3319,"totalTrials":183,"cells":3348},{"EARLY_PHASE1":3349,"PHASE1":3351,"PHASE2":3357,"PHASE3":3359,"PHASE4":3361,"NA":3363},{"trials":3350,"activeCount":75},[],{"trials":3352,"activeCount":75},[3353],{"nctId":3307,"briefTitle":3308,"status":134,"phases":3354,"primaryCompletion":3310,"completion":3311,"start":3312,"enrollment":3313,"conditions":3355,"interventions":3356},[63],[3315,3316],[3300,3318,3319,3320],{"trials":3358,"activeCount":75},[],{"trials":3360,"activeCount":75},[],{"trials":3362,"activeCount":75},[],{"trials":3364,"activeCount":75},[],{"intervention":3320,"totalTrials":183,"cells":3366},{"EARLY_PHASE1":3367,"PHASE1":3369,"PHASE2":3375,"PHASE3":3377,"PHASE4":3379,"NA":3381},{"trials":3368,"activeCount":75},[],{"trials":3370,"activeCount":75},[3371],{"nctId":3307,"briefTitle":3308,"status":134,"phases":3372,"primaryCompletion":3310,"completion":3311,"start":3312,"enrollment":3313,"conditions":3373,"interventions":3374},[63],[3315,3316],[3300,3318,3319,3320],{"trials":3376,"activeCount":75},[],{"trials":3378,"activeCount":75},[],{"trials":3380,"activeCount":75},[],{"trials":3382,"activeCount":75},[],{"intervention":3384,"totalTrials":183,"cells":3385},"ixabepilone",{"EARLY_PHASE1":3386,"PHASE1":3388,"PHASE2":3399,"PHASE3":3401,"PHASE4":3403,"NA":3405},{"trials":3387,"activeCount":75},[],{"trials":3389,"activeCount":75},[3390],{"nctId":3391,"briefTitle":3392,"status":81,"phases":3393,"primaryCompletion":2185,"completion":3394,"start":3395,"enrollment":1352,"conditions":3396,"interventions":3398},"NCT00030108","Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy",[63],"2010-04","2001-11",[1343,1468,3397,33,87,23,1469,1344,1470,1471],"Extragonadal Germ Cell Tumor",[3384],{"trials":3400,"activeCount":75},[],{"trials":3402,"activeCount":75},[],{"trials":3404,"activeCount":75},[],{"trials":3406,"activeCount":75},[],{"intervention":92,"totalTrials":183,"cells":3408},{"EARLY_PHASE1":3409,"PHASE1":3411,"PHASE2":3417,"PHASE3":3419,"PHASE4":3421,"NA":3423},{"trials":3410,"activeCount":75},[],{"trials":3412,"activeCount":75},[3413],{"nctId":79,"briefTitle":80,"status":81,"phases":3414,"completion":83,"start":84,"enrollment":18,"conditions":3415,"interventions":3416},[63],[86,87,20,88,89,90],[70,92,93,94,95,96,97,98,99,100,101,102],{"trials":3418,"activeCount":75},[],{"trials":3420,"activeCount":75},[],{"trials":3422,"activeCount":75},[],{"trials":3424,"activeCount":75},[],{"intervention":93,"totalTrials":183,"cells":3426},{"EARLY_PHASE1":3427,"PHASE1":3429,"PHASE2":3435,"PHASE3":3437,"PHASE4":3439,"NA":3441},{"trials":3428,"activeCount":75},[],{"trials":3430,"activeCount":75},[3431],{"nctId":79,"briefTitle":80,"status":81,"phases":3432,"completion":83,"start":84,"enrollment":18,"conditions":3433,"interventions":3434},[63],[86,87,20,88,89,90],[70,92,93,94,95,96,97,98,99,100,101,102],{"trials":3436,"activeCount":75},[],{"trials":3438,"activeCount":75},[],{"trials":3440,"activeCount":75},[],{"trials":3442,"activeCount":75},[],{"intervention":94,"totalTrials":183,"cells":3444},{"EARLY_PHASE1":3445,"PHASE1":3447,"PHASE2":3453,"PHASE3":3455,"PHASE4":3457,"NA":3459},{"trials":3446,"activeCount":75},[],{"trials":3448,"activeCount":75},[3449],{"nctId":79,"briefTitle":80,"status":81,"phases":3450,"completion":83,"start":84,"enrollment":18,"conditions":3451,"interventions":3452},[63],[86,87,20,88,89,90],[70,92,93,94,95,96,97,98,99,100,101,102],{"trials":3454,"activeCount":75},[],{"trials":3456,"activeCount":75},[],{"trials":3458,"activeCount":75},[],{"trials":3460,"activeCount":75},[],{"intervention":3462,"totalTrials":183,"cells":3463},"PEG-interferon alfa-2a",{"EARLY_PHASE1":3464,"PHASE1":3466,"PHASE2":3476,"PHASE3":3478,"PHASE4":3480,"NA":3482},{"trials":3465,"activeCount":75},[],{"trials":3467,"activeCount":75},[3468],{"nctId":3469,"briefTitle":3470,"status":81,"phases":3471,"completion":647,"start":1581,"enrollment":3472,"conditions":3473,"interventions":3475},"NCT00253474","PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma",[63],36,[3474,1471],"Neoplasm of Uncertain Malignant Potential",[3462],{"trials":3477,"activeCount":75},[],{"trials":3479,"activeCount":75},[],{"trials":3481,"activeCount":75},[],{"trials":3483,"activeCount":75},[],{"intervention":3485,"totalTrials":183,"cells":3486},"tipifarnib",{"EARLY_PHASE1":3487,"PHASE1":3489,"PHASE2":3497,"PHASE3":3499,"PHASE4":3501,"NA":3503},{"trials":3488,"activeCount":75},[],{"trials":3490,"activeCount":75},[3491],{"nctId":3492,"briefTitle":3493,"status":81,"phases":3494,"completion":1875,"start":2954,"conditions":3495,"interventions":3496},"NCT00022451","Tipifarnib in Treating Young Patients With Refractory Leukemia",[63],[87],[3485],{"trials":3498,"activeCount":75},[],{"trials":3500,"activeCount":75},[],{"trials":3502,"activeCount":75},[],{"trials":3504,"activeCount":75},[],{"intervention":231,"totalTrials":183,"cells":3506},{"EARLY_PHASE1":3507,"PHASE1":3509,"PHASE2":3515,"PHASE3":3517,"PHASE4":3519,"NA":3521},{"trials":3508,"activeCount":75},[],{"trials":3510,"activeCount":75},[3511],{"nctId":222,"briefTitle":223,"status":81,"phases":3512,"primaryCompletion":225,"completion":225,"start":226,"enrollment":227,"conditions":3513,"interventions":3514},[63],[229],[55,231],{"trials":3516,"activeCount":75},[],{"trials":3518,"activeCount":75},[],{"trials":3520,"activeCount":75},[],{"trials":3522,"activeCount":75},[],{"intervention":3524,"totalTrials":183,"cells":3525},"veliparib",{"EARLY_PHASE1":3526,"PHASE1":3528,"PHASE2":3537,"PHASE3":3539,"PHASE4":3541,"NA":3543},{"trials":3527,"activeCount":75},[],{"trials":3529,"activeCount":75},[3530],{"nctId":3531,"briefTitle":3532,"status":81,"phases":3533,"primaryCompletion":1300,"completion":390,"start":1315,"enrollment":3534,"conditions":3535,"interventions":3536},"NCT00387608","ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer",[63],23,[87,20,17],[3524],{"trials":3538,"activeCount":75},[],{"trials":3540,"activeCount":75},[],{"trials":3542,"activeCount":75},[],{"trials":3544,"activeCount":75},[],{"intervention":3546,"totalTrials":183,"cells":3547},"bevacizumab",{"EARLY_PHASE1":3548,"PHASE1":3550,"PHASE2":3562,"PHASE3":3564,"PHASE4":3566,"NA":3568},{"trials":3549,"activeCount":75},[],{"trials":3551,"activeCount":75},[3552],{"nctId":3553,"briefTitle":3554,"status":81,"phases":3555,"primaryCompletion":3556,"completion":1281,"start":773,"enrollment":3557,"conditions":3558,"interventions":3560},"NCT00734890","Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma",[63],"2010-06",18,[975,20,3559,977,17],"Lymphoproliferative Disorder",[3546,3561],"vandetanib",{"trials":3563,"activeCount":75},[],{"trials":3565,"activeCount":75},[],{"trials":3567,"activeCount":75},[],{"trials":3569,"activeCount":75},[],{"intervention":3561,"totalTrials":183,"cells":3571},{"EARLY_PHASE1":3572,"PHASE1":3574,"PHASE2":3580,"PHASE3":3582,"PHASE4":3584,"NA":3586},{"trials":3573,"activeCount":75},[],{"trials":3575,"activeCount":75},[3576],{"nctId":3553,"briefTitle":3554,"status":81,"phases":3577,"primaryCompletion":3556,"completion":1281,"start":773,"enrollment":3557,"conditions":3578,"interventions":3579},[63],[975,20,3559,977,17],[3546,3561],{"trials":3581,"activeCount":75},[],{"trials":3583,"activeCount":75},[],{"trials":3585,"activeCount":75},[],{"trials":3587,"activeCount":75},[],{"intervention":3589,"totalTrials":183,"cells":3590},"Recombinant Tissue Plasminogen Activator",{"EARLY_PHASE1":3591,"PHASE1":3593,"PHASE2":3606,"PHASE3":3608,"PHASE4":3610,"NA":3612},{"trials":3592,"activeCount":75},[],{"trials":3594,"activeCount":75},[3595],{"nctId":3596,"briefTitle":3597,"status":81,"phases":3598,"completion":897,"start":3599,"enrollment":18,"conditions":3600,"interventions":3603},"NCT00001713","Treatment for Blood Clots in the Veins of the Legs",[63],"1998-02",[3601,3602],"Embolism","Thrombophlebitis",[3589,3604,3605],"Heparin","Warfarin",{"trials":3607,"activeCount":75},[],{"trials":3609,"activeCount":75},[],{"trials":3611,"activeCount":75},[],{"trials":3613,"activeCount":75},[],{"intervention":3604,"totalTrials":183,"cells":3615},{"EARLY_PHASE1":3616,"PHASE1":3618,"PHASE2":3624,"PHASE3":3626,"PHASE4":3628,"NA":3630},{"trials":3617,"activeCount":75},[],{"trials":3619,"activeCount":75},[3620],{"nctId":3596,"briefTitle":3597,"status":81,"phases":3621,"completion":897,"start":3599,"enrollment":18,"conditions":3622,"interventions":3623},[63],[3601,3602],[3589,3604,3605],{"trials":3625,"activeCount":75},[],{"trials":3627,"activeCount":75},[],{"trials":3629,"activeCount":75},[],{"trials":3631,"activeCount":75},[],{"intervention":3605,"totalTrials":183,"cells":3633},{"EARLY_PHASE1":3634,"PHASE1":3636,"PHASE2":3642,"PHASE3":3644,"PHASE4":3646,"NA":3648},{"trials":3635,"activeCount":75},[],{"trials":3637,"activeCount":75},[3638],{"nctId":3596,"briefTitle":3597,"status":81,"phases":3639,"completion":897,"start":3599,"enrollment":18,"conditions":3640,"interventions":3641},[63],[3601,3602],[3589,3604,3605],{"trials":3643,"activeCount":75},[],{"trials":3645,"activeCount":75},[],{"trials":3647,"activeCount":75},[],{"trials":3649,"activeCount":75},[],{"intervention":979,"totalTrials":183,"cells":3651},{"EARLY_PHASE1":3652,"PHASE1":3654,"PHASE2":3660,"PHASE3":3662,"PHASE4":3664,"NA":3666},{"trials":3653,"activeCount":75},[],{"trials":3655,"activeCount":75},[3656],{"nctId":965,"briefTitle":966,"status":81,"phases":3657,"completion":968,"start":969,"enrollment":970,"conditions":3658,"interventions":3659},[63],[901,972,973,974,23,975,20,976,977,17],[952,979,934],{"trials":3661,"activeCount":75},[],{"trials":3663,"activeCount":75},[],{"trials":3665,"activeCount":75},[],{"trials":3667,"activeCount":75},[],{"intervention":1356,"totalTrials":183,"cells":3669},{"EARLY_PHASE1":3670,"PHASE1":3672,"PHASE2":3678,"PHASE3":3680,"PHASE4":3682,"NA":3684},{"trials":3671,"activeCount":75},[],{"trials":3673,"activeCount":75},[3674],{"nctId":1348,"briefTitle":1349,"status":81,"phases":3675,"primaryCompletion":108,"completion":1351,"start":124,"enrollment":1352,"conditions":3676,"interventions":3677},[63],[1354],[1356,1330],{"trials":3679,"activeCount":75},[],{"trials":3681,"activeCount":75},[],{"trials":3683,"activeCount":75},[],{"trials":3685,"activeCount":75},[],{"intervention":2782,"totalTrials":183,"cells":3687},{"EARLY_PHASE1":3688,"PHASE1":3690,"PHASE2":3696,"PHASE3":3698,"PHASE4":3700,"NA":3702},{"trials":3689,"activeCount":75},[],{"trials":3691,"activeCount":75},[3692],{"nctId":2773,"briefTitle":2774,"status":81,"phases":3693,"primaryCompletion":2776,"completion":2777,"start":2778,"enrollment":2779,"conditions":3694,"interventions":3695},[63],[31],[2782,2783,2743],{"trials":3697,"activeCount":75},[],{"trials":3699,"activeCount":75},[],{"trials":3701,"activeCount":75},[],{"trials":3703,"activeCount":75},[],{"intervention":2783,"totalTrials":183,"cells":3705},{"EARLY_PHASE1":3706,"PHASE1":3708,"PHASE2":3714,"PHASE3":3716,"PHASE4":3718,"NA":3720},{"trials":3707,"activeCount":75},[],{"trials":3709,"activeCount":75},[3710],{"nctId":2773,"briefTitle":2774,"status":81,"phases":3711,"primaryCompletion":2776,"completion":2777,"start":2778,"enrollment":2779,"conditions":3712,"interventions":3713},[63],[31],[2782,2783,2743],{"trials":3715,"activeCount":75},[],{"trials":3717,"activeCount":75},[],{"trials":3719,"activeCount":75},[],{"trials":3721,"activeCount":75},[],{"intervention":2716,"totalTrials":183,"cells":3723},{"EARLY_PHASE1":3724,"PHASE1":3726,"PHASE2":3732,"PHASE3":3734,"PHASE4":3736,"NA":3738},{"trials":3725,"activeCount":75},[],{"trials":3727,"activeCount":75},[3728],{"nctId":2707,"briefTitle":2708,"status":81,"phases":3729,"primaryCompletion":2710,"completion":2710,"start":2711,"enrollment":2712,"conditions":3730,"interventions":3731},[63],[778,2714],[2716,2678,2717],{"trials":3733,"activeCount":75},[],{"trials":3735,"activeCount":75},[],{"trials":3737,"activeCount":75},[],{"trials":3739,"activeCount":75},[],{"intervention":2717,"totalTrials":183,"cells":3741},{"EARLY_PHASE1":3742,"PHASE1":3744,"PHASE2":3750,"PHASE3":3752,"PHASE4":3754,"NA":3756},{"trials":3743,"activeCount":75},[],{"trials":3745,"activeCount":75},[3746],{"nctId":2707,"briefTitle":2708,"status":81,"phases":3747,"primaryCompletion":2710,"completion":2710,"start":2711,"enrollment":2712,"conditions":3748,"interventions":3749},[63],[778,2714],[2716,2678,2717],{"trials":3751,"activeCount":75},[],{"trials":3753,"activeCount":75},[],{"trials":3755,"activeCount":75},[],{"trials":3757,"activeCount":75},[],{"intervention":1364,"totalTrials":183,"cells":3759},{"EARLY_PHASE1":3760,"PHASE1":3762,"PHASE2":3768,"PHASE3":3770,"PHASE4":3772,"NA":3774},{"trials":3761,"activeCount":75},[],{"trials":3763,"activeCount":75},[3764],{"nctId":1358,"briefTitle":1359,"status":81,"phases":3765,"primaryCompletion":122,"completion":1361,"start":146,"conditions":3766,"interventions":3767},[63],[17],[1330,1364],{"trials":3769,"activeCount":75},[],{"trials":3771,"activeCount":75},[],{"trials":3773,"activeCount":75},[],{"trials":3775,"activeCount":75},[],{"intervention":113,"totalTrials":183,"cells":3777},{"EARLY_PHASE1":3778,"PHASE1":3780,"PHASE2":3786,"PHASE3":3788,"PHASE4":3790,"NA":3792},{"trials":3779,"activeCount":75},[],{"trials":3781,"activeCount":75},[3782],{"nctId":104,"briefTitle":105,"status":81,"phases":3783,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":3784,"interventions":3785},[63],[29],[113,114,70,115,116,117,95,100],{"trials":3787,"activeCount":75},[],{"trials":3789,"activeCount":75},[],{"trials":3791,"activeCount":75},[],{"trials":3793,"activeCount":75},[],{"intervention":3795,"totalTrials":183,"cells":3796},"Irinotecan",{"EARLY_PHASE1":3797,"PHASE1":3799,"PHASE2":3811,"PHASE3":3813,"PHASE4":3815,"NA":3817},{"trials":3798,"activeCount":75},[],{"trials":3800,"activeCount":75},[3801],{"nctId":3802,"briefTitle":3803,"status":134,"phases":3804,"completion":3805,"start":3805,"enrollment":885,"conditions":3806,"interventions":3810},"NCT01336985","Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads",[63],"2011-03-28",[3807,3808,3809],"Neoplasm Metastases","Melanoma","Colorectal Neoplasms",[3795],{"trials":3812,"activeCount":75},[],{"trials":3814,"activeCount":75},[],{"trials":3816,"activeCount":75},[],{"trials":3818,"activeCount":75},[],{"intervention":3820,"totalTrials":183,"cells":3821},"ANS-6637",{"EARLY_PHASE1":3822,"PHASE1":3824,"PHASE2":3836,"PHASE3":3838,"PHASE4":3840,"NA":3842},{"trials":3823,"activeCount":75},[],{"trials":3825,"activeCount":75},[3826],{"nctId":3827,"briefTitle":3828,"status":81,"phases":3829,"primaryCompletion":3830,"completion":3831,"start":3832,"enrollment":1318,"conditions":3833,"interventions":3835},"NCT03831971","The Influence of ANS-6637 on Midazolam Pharmacokinetics in Healthy Volunteers",[63],"2019-08-09","2019-12-30","2019-03-01",[3834],"Opiod Use Disorder",[3820],{"trials":3837,"activeCount":75},[],{"trials":3839,"activeCount":75},[],{"trials":3841,"activeCount":75},[],{"trials":3843,"activeCount":75},[],{"intervention":3845,"totalTrials":183,"cells":3846},"fenretinide lipid matrix",{"EARLY_PHASE1":3847,"PHASE1":3849,"PHASE2":3859,"PHASE3":3861,"PHASE4":3863,"NA":3865},{"trials":3848,"activeCount":75},[],{"trials":3850,"activeCount":75},[3851],{"nctId":3852,"briefTitle":3853,"status":81,"phases":3854,"primaryCompletion":83,"completion":3855,"start":3856,"enrollment":1352,"conditions":3857,"interventions":3858},"NCT00589381","Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma",[63],"2011-03","2007-08",[20,17],[3845],{"trials":3860,"activeCount":75},[],{"trials":3862,"activeCount":75},[],{"trials":3864,"activeCount":75},[],{"trials":3866,"activeCount":75},[],{"intervention":202,"totalTrials":183,"cells":3868},{"EARLY_PHASE1":3869,"PHASE1":3871,"PHASE2":3877,"PHASE3":3879,"PHASE4":3881,"NA":3883},{"trials":3870,"activeCount":75},[],{"trials":3872,"activeCount":75},[3873],{"nctId":194,"briefTitle":195,"status":81,"phases":3874,"completion":197,"start":198,"enrollment":199,"conditions":3875,"interventions":3876},[63],[15],[202,182],{"trials":3878,"activeCount":75},[],{"trials":3880,"activeCount":75},[],{"trials":3882,"activeCount":75},[],{"trials":3884,"activeCount":75},[],{"intervention":3886,"totalTrials":183,"cells":3887},"ABT-751",{"EARLY_PHASE1":3888,"PHASE1":3890,"PHASE2":3899,"PHASE3":3901,"PHASE4":3903,"NA":3905},{"trials":3889,"activeCount":75},[],{"trials":3891,"activeCount":75},[3892],{"nctId":3893,"briefTitle":3894,"status":81,"phases":3895,"primaryCompletion":1466,"completion":1466,"start":911,"enrollment":3896,"conditions":3897,"interventions":3898},"NCT00036959","ABT-751 in Treating Young Patients With Refractory Solid Tumors",[63],90,[1343,1468,3397,33,23,1469,1344,1470,1471],[3886],{"trials":3900,"activeCount":75},[],{"trials":3902,"activeCount":75},[],{"trials":3904,"activeCount":75},[],{"trials":3906,"activeCount":75},[],{"intervention":1575,"totalTrials":183,"cells":3908},{"EARLY_PHASE1":3909,"PHASE1":3911,"PHASE2":3917,"PHASE3":3919,"PHASE4":3921,"NA":3923},{"trials":3910,"activeCount":75},[],{"trials":3912,"activeCount":75},[3913],{"nctId":1567,"briefTitle":1568,"status":81,"phases":3914,"primaryCompletion":710,"completion":710,"start":1570,"enrollment":1571,"conditions":3915,"interventions":3916},[63],[1573],[1575,1560,1576],{"trials":3918,"activeCount":75},[],{"trials":3920,"activeCount":75},[],{"trials":3922,"activeCount":75},[],{"trials":3924,"activeCount":75},[],{"intervention":3926,"totalTrials":183,"cells":3927},"Ginkgo Biloba",{"EARLY_PHASE1":3928,"PHASE1":3930,"PHASE2":3938,"PHASE3":3940,"PHASE4":3942,"NA":3944},{"trials":3929,"activeCount":75},[],{"trials":3931,"activeCount":75},[3932],{"nctId":3933,"briefTitle":3934,"status":81,"phases":3935,"completion":526,"start":2955,"enrollment":27,"conditions":3936,"interventions":3937},"NCT00011063","Effect of Ginkgo Biloba on Phenytoin Elimination",[63],[15],[3926],{"trials":3939,"activeCount":75},[],{"trials":3941,"activeCount":75},[],{"trials":3943,"activeCount":75},[],{"trials":3945,"activeCount":75},[],{"intervention":3947,"totalTrials":183,"cells":3948},"18F-FDOPA",{"EARLY_PHASE1":3949,"PHASE1":3951,"PHASE2":3965,"PHASE3":3967,"PHASE4":3969,"NA":3971},{"trials":3950,"activeCount":75},[],{"trials":3952,"activeCount":75},[3953],{"nctId":3954,"briefTitle":3955,"status":81,"phases":3956,"primaryCompletion":3957,"completion":3957,"start":3958,"enrollment":3959,"conditions":3960,"interventions":3963},"NCT03581305","PET Imaging of the Dopaminergic and Serotonergic Systems in Treated HIV Positive Subjects",[63],"2022-04-06","2018-11-20",46,[3961,714,3962],"Depression","HIV-Associated Cognitive Motor Complex",[3947,3964],"11C-DASB",{"trials":3966,"activeCount":75},[],{"trials":3968,"activeCount":75},[],{"trials":3970,"activeCount":75},[],{"trials":3972,"activeCount":75},[],{"intervention":3964,"totalTrials":183,"cells":3974},{"EARLY_PHASE1":3975,"PHASE1":3977,"PHASE2":3983,"PHASE3":3985,"PHASE4":3987,"NA":3989},{"trials":3976,"activeCount":75},[],{"trials":3978,"activeCount":75},[3979],{"nctId":3954,"briefTitle":3955,"status":81,"phases":3980,"primaryCompletion":3957,"completion":3957,"start":3958,"enrollment":3959,"conditions":3981,"interventions":3982},[63],[3961,714,3962],[3947,3964],{"trials":3984,"activeCount":75},[],{"trials":3986,"activeCount":75},[],{"trials":3988,"activeCount":75},[],{"trials":3990,"activeCount":75},[],{"intervention":3992,"totalTrials":183,"cells":3993},"Atovaquone 750 mg twice daily",{"EARLY_PHASE1":3994,"PHASE1":3996,"PHASE2":4008,"PHASE3":4010,"PHASE4":4012,"NA":4014},{"trials":3995,"activeCount":75},[],{"trials":3997,"activeCount":75},[3998],{"nctId":3999,"briefTitle":4000,"status":81,"phases":4001,"primaryCompletion":3312,"completion":3312,"start":4002,"enrollment":3472,"conditions":4003,"interventions":4006},"NCT01479361","Antiretroviral Drug Interaction Study in Volunteers With HIV",[63],"2011-10-31",[778,4004,4005],"PCP","Toxoplasmosis",[3992,4007],"Atovaquone 1500 mg twice daily",{"trials":4009,"activeCount":75},[],{"trials":4011,"activeCount":75},[],{"trials":4013,"activeCount":75},[],{"trials":4015,"activeCount":75},[],{"intervention":4007,"totalTrials":183,"cells":4017},{"EARLY_PHASE1":4018,"PHASE1":4020,"PHASE2":4026,"PHASE3":4028,"PHASE4":4030,"NA":4032},{"trials":4019,"activeCount":75},[],{"trials":4021,"activeCount":75},[4022],{"nctId":3999,"briefTitle":4000,"status":81,"phases":4023,"primaryCompletion":3312,"completion":3312,"start":4002,"enrollment":3472,"conditions":4024,"interventions":4025},[63],[778,4004,4005],[3992,4007],{"trials":4027,"activeCount":75},[],{"trials":4029,"activeCount":75},[],{"trials":4031,"activeCount":75},[],{"trials":4033,"activeCount":75},[],{"intervention":128,"totalTrials":183,"cells":4035},{"EARLY_PHASE1":4036,"PHASE1":4038,"PHASE2":4044,"PHASE3":4046,"PHASE4":4048,"NA":4050},{"trials":4037,"activeCount":75},[],{"trials":4039,"activeCount":75},[4040],{"nctId":119,"briefTitle":120,"status":81,"phases":4041,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":4042,"interventions":4043},[63],[29],[114,70,128,116,117,95,100],{"trials":4045,"activeCount":75},[],{"trials":4047,"activeCount":75},[],{"trials":4049,"activeCount":75},[],{"trials":4051,"activeCount":75},[],{"intervention":4053,"totalTrials":183,"cells":4054},"recombinant interleukin-7",{"EARLY_PHASE1":4055,"PHASE1":4057,"PHASE2":4067,"PHASE3":4069,"PHASE4":4071,"NA":4073},{"trials":4056,"activeCount":75},[],{"trials":4058,"activeCount":75},[4059],{"nctId":4060,"briefTitle":4061,"status":81,"phases":4062,"completion":4063,"start":4064,"enrollment":1352,"conditions":4065,"interventions":4066},"NCT00062049","Interleukin-7 in Treating Patients With Refractory Solid Tumors",[63],"2011-05","2003-04",[17],[4053],{"trials":4068,"activeCount":75},[],{"trials":4070,"activeCount":75},[],{"trials":4072,"activeCount":75},[],{"trials":4074,"activeCount":75},[],{"intervention":4076,"totalTrials":183,"cells":4077},"Resiniferatoxin",{"EARLY_PHASE1":4078,"PHASE1":4080,"PHASE2":4092,"PHASE3":4094,"PHASE4":4096,"NA":4098},{"trials":4079,"activeCount":75},[],{"trials":4081,"activeCount":75},[4082],{"nctId":4083,"briefTitle":4084,"status":81,"phases":4085,"primaryCompletion":4086,"completion":4087,"start":4088,"enrollment":156,"conditions":4089,"interventions":4091},"NCT05695339","Resiniferatoxin for the Management of Refractory Morton s Neuroma Pain",[63],"2025-10-12","2025-10-15","2025-03-13",[4090],"Morton's Neuroma",[4076],{"trials":4093,"activeCount":75},[],{"trials":4095,"activeCount":75},[],{"trials":4097,"activeCount":75},[],{"trials":4099,"activeCount":75},[],{"intervention":4101,"totalTrials":183,"cells":4102},"AG-348",{"EARLY_PHASE1":4103,"PHASE1":4113,"PHASE2":4115,"PHASE3":4117,"PHASE4":4119,"NA":4121},{"trials":4104,"activeCount":75},[4105],{"nctId":4106,"briefTitle":4107,"status":81,"phases":4108,"primaryCompletion":4109,"completion":4109,"start":4110,"enrollment":21,"conditions":4111,"interventions":4112},"NCT04000165","A Dose-Finding Study of AG-348 in Sickle Cell Disease",[62],"2021-06-21","2019-07-11",[1573],[4101],{"trials":4114,"activeCount":75},[],{"trials":4116,"activeCount":75},[],{"trials":4118,"activeCount":75},[],{"trials":4120,"activeCount":75},[],{"trials":4122,"activeCount":75},[],{"intervention":100,"totalTrials":71,"cells":4124},{"EARLY_PHASE1":4125,"PHASE1":4127,"PHASE2":4141,"PHASE3":4159,"PHASE4":4161,"NA":4163},{"trials":4126,"activeCount":75},[],{"trials":4128,"activeCount":75},[4129,4133,4137],{"nctId":79,"briefTitle":80,"status":81,"phases":4130,"completion":83,"start":84,"enrollment":18,"conditions":4131,"interventions":4132},[63],[86,87,20,88,89,90],[70,92,93,94,95,96,97,98,99,100,101,102],{"nctId":104,"briefTitle":105,"status":81,"phases":4134,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":4135,"interventions":4136},[63],[29],[113,114,70,115,116,117,95,100],{"nctId":119,"briefTitle":120,"status":81,"phases":4138,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":4139,"interventions":4140},[63],[29],[114,70,128,116,117,95,100],{"trials":4142,"activeCount":75},[4143,4147,4151,4155],{"nctId":132,"briefTitle":133,"status":134,"phases":4144,"completion":136,"start":137,"enrollment":138,"conditions":4145,"interventions":4146},[64],[29],[114,70,116,95,100],{"nctId":142,"briefTitle":143,"status":81,"phases":4148,"primaryCompletion":145,"completion":145,"start":146,"enrollment":147,"conditions":4149,"interventions":4150},[64],[29],[114,70,117,95,100],{"nctId":151,"briefTitle":152,"status":134,"phases":4152,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":4153,"interventions":4154},[64],[33,29,17],[114,159,160,70,95,100],{"nctId":162,"briefTitle":163,"status":81,"phases":4156,"primaryCompletion":165,"completion":123,"start":166,"enrollment":8,"conditions":4157,"interventions":4158},[63,64],[29],[114,70,115,169,117,95,100],{"trials":4160,"activeCount":75},[],{"trials":4162,"activeCount":75},[],{"trials":4164,"activeCount":75},[4165],{"nctId":453,"briefTitle":454,"status":431,"phases":4166,"completion":456,"start":457,"enrollment":75,"conditions":4167,"interventions":4168},[67],[20],[460,95,100],{"intervention":114,"totalTrials":9,"cells":4170},{"EARLY_PHASE1":4171,"PHASE1":4173,"PHASE2":4183,"PHASE3":4201,"PHASE4":4203,"NA":4205},{"trials":4172,"activeCount":75},[],{"trials":4174,"activeCount":75},[4175,4179],{"nctId":104,"briefTitle":105,"status":81,"phases":4176,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":4177,"interventions":4178},[63],[29],[113,114,70,115,116,117,95,100],{"nctId":119,"briefTitle":120,"status":81,"phases":4180,"primaryCompletion":122,"completion":123,"start":124,"enrollment":125,"conditions":4181,"interventions":4182},[63],[29],[114,70,128,116,117,95,100],{"trials":4184,"activeCount":75},[4185,4189,4193,4197],{"nctId":132,"briefTitle":133,"status":134,"phases":4186,"completion":136,"start":137,"enrollment":138,"conditions":4187,"interventions":4188},[64],[29],[114,70,116,95,100],{"nctId":142,"briefTitle":143,"status":81,"phases":4190,"primaryCompletion":145,"completion":145,"start":146,"enrollment":147,"conditions":4191,"interventions":4192},[64],[29],[114,70,117,95,100],{"nctId":151,"briefTitle":152,"status":134,"phases":4194,"primaryCompletion":154,"completion":154,"start":155,"enrollment":156,"conditions":4195,"interventions":4196},[64],[33,29,17],[114,159,160,70,95,100],{"nctId":162,"briefTitle":163,"status":81,"phases":4198,"primaryCompletion":165,"completion":123,"start":166,"enrollment":8,"conditions":4199,"interventions":4200},[63,64],[29],[114,70,115,169,117,95,100],{"trials":4202,"activeCount":75},[],{"trials":4204,"activeCount":75},[],{"trials":4206,"activeCount":75},[4207],{"nctId":443,"briefTitle":444,"status":445,"phases":4208,"conditions":4209,"interventions":4210},[],[],[449,268,269,450,451],{"intervention":784,"totalTrials":156,"cells":4212},{"EARLY_PHASE1":4213,"PHASE1":4215,"PHASE2":4221,"PHASE3":4223,"PHASE4":4225,"NA":4231},{"trials":4214,"activeCount":75},[],{"trials":4216,"activeCount":75},[4217],{"nctId":2685,"briefTitle":2686,"status":81,"phases":4218,"primaryCompletion":2688,"completion":2688,"start":2689,"enrollment":2690,"conditions":4219,"interventions":4220},[63],[778,2692,2693,2694,2695],[2692,2678,784],{"trials":4222,"activeCount":75},[],{"trials":4224,"activeCount":75},[],{"trials":4226,"activeCount":75},[4227],{"nctId":770,"briefTitle":771,"status":81,"phases":4228,"primaryCompletion":773,"completion":774,"start":775,"enrollment":776,"conditions":4229,"interventions":4230},[66],[778],[757,780,781,782,783,784],{"trials":4232,"activeCount":75},[4233],{"nctId":4234,"briefTitle":4235,"status":81,"phases":4236,"primaryCompletion":1316,"completion":1316,"start":122,"enrollment":3313,"conditions":4237,"interventions":4238},"NCT00474201","Drug Interaction Study of Lopinavir\u002FRitonavir and Gemfibrozil",[67],[31],[784,3146],{"intervention":4240,"totalTrials":156,"cells":4241},"proteomic profiling",{"EARLY_PHASE1":4242,"PHASE1":4244,"PHASE2":4246,"PHASE3":4248,"PHASE4":4250,"NA":4252},{"trials":4243,"activeCount":75},[],{"trials":4245,"activeCount":75},[],{"trials":4247,"activeCount":75},[],{"trials":4249,"activeCount":75},[],{"trials":4251,"activeCount":75},[],{"trials":4253,"activeCount":75},[4254,4261,4269],{"nctId":4255,"briefTitle":4256,"status":81,"phases":4257,"primaryCompletion":1436,"completion":2185,"start":166,"enrollment":4258,"conditions":4259,"interventions":4260},"NCT00066664","Serum Protein Patterns in Participants With Mycosis Fungoides\u002FCutaneous T-Cell Lymphoma, Psoriasis, or Normal Skin",[67],423,[20],[4240],{"nctId":4262,"briefTitle":4263,"status":81,"phases":4264,"completion":390,"start":4265,"enrollment":4266,"conditions":4267,"interventions":4268},"NCT00559598","Blood Proteins in Finding Pancreatic Cancer and Extrahepatic Biliary Tract Cancer",[],"2004-08",502,[973,976],[4240],{"nctId":4270,"briefTitle":4271,"status":81,"phases":4272,"completion":3556,"start":775,"enrollment":4273,"conditions":4274,"interventions":4275},"NCT00430053","Clinical Evaluations and Laboratory Studies to Study the Disease Course in Patients With Cutaneous T-Cell Lymphoma",[],100,[20],[4276,4277,4240],"gene rearrangement analysis","polymerase chain reaction",{"intervention":4279,"totalTrials":187,"cells":4280},"microarray analysis",{"EARLY_PHASE1":4281,"PHASE1":4283,"PHASE2":4285,"PHASE3":4287,"PHASE4":4289,"NA":4291},{"trials":4282,"activeCount":75},[],{"trials":4284,"activeCount":75},[],{"trials":4286,"activeCount":75},[],{"trials":4288,"activeCount":75},[],{"trials":4290,"activeCount":75},[],{"trials":4292,"activeCount":75},[4293,4299],{"nctId":4294,"briefTitle":4295,"status":81,"phases":4296,"completion":3856,"start":84,"enrollment":624,"conditions":4297,"interventions":4298},"NCT00080860","Sentinel Lymph Node Biopsy and Primary Tumor Gene Expression Profiling in Finding Axillary Lymph Node Metastases in Women Who Have Received Neoadjuvant Therapy for Stage II, Stage III, or Stage IV Breast Cancer",[67],[26],[4279],{"nctId":4300,"briefTitle":4301,"status":134,"phases":4302,"primaryCompletion":1652,"completion":1652,"start":1652,"enrollment":4303,"conditions":4304,"interventions":4305},"NCT00904514","Study of Previously Collected and Stored Tissue Samples From Patients Previously Enrolled in a Completed National Cancer Institute Clinical Trial",[],241,[3188],[4306,4279,4307,4277],"gene expression analysis","mutation analysis",{"intervention":3146,"totalTrials":187,"cells":4309},{"EARLY_PHASE1":4310,"PHASE1":4312,"PHASE2":4318,"PHASE3":4320,"PHASE4":4322,"NA":4324},{"trials":4311,"activeCount":75},[],{"trials":4313,"activeCount":75},[4314],{"nctId":3139,"briefTitle":3140,"status":81,"phases":4315,"completion":3142,"start":1960,"enrollment":3143,"conditions":4316,"interventions":4317},[63],[714],[3132,3146,3147],{"trials":4319,"activeCount":75},[],{"trials":4321,"activeCount":75},[],{"trials":4323,"activeCount":75},[],{"trials":4325,"activeCount":75},[4326],{"nctId":4234,"briefTitle":4235,"status":81,"phases":4327,"primaryCompletion":1316,"completion":1316,"start":122,"enrollment":3313,"conditions":4328,"interventions":4329},[67],[31],[784,3146],{"intervention":4307,"totalTrials":187,"cells":4331},{"EARLY_PHASE1":4332,"PHASE1":4334,"PHASE2":4336,"PHASE3":4338,"PHASE4":4340,"NA":4342},{"trials":4333,"activeCount":75},[],{"trials":4335,"activeCount":75},[],{"trials":4337,"activeCount":75},[],{"trials":4339,"activeCount":75},[],{"trials":4341,"activeCount":75},[],{"trials":4343,"activeCount":75},[4344,4353],{"nctId":4345,"briefTitle":4346,"status":81,"phases":4347,"primaryCompletion":1445,"completion":1445,"start":4348,"enrollment":4349,"conditions":4350,"interventions":4352},"NCT00075348","Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome",[],"2003-12",260,[33,4351],"Von Hippel-lindau Syndrome",[4307],{"nctId":4300,"briefTitle":4301,"status":134,"phases":4354,"primaryCompletion":1652,"completion":1652,"start":1652,"enrollment":4303,"conditions":4355,"interventions":4356},[],[3188],[4306,4279,4307,4277],{"intervention":4277,"totalTrials":187,"cells":4358},{"EARLY_PHASE1":4359,"PHASE1":4361,"PHASE2":4363,"PHASE3":4365,"PHASE4":4367,"NA":4369},{"trials":4360,"activeCount":75},[],{"trials":4362,"activeCount":75},[],{"trials":4364,"activeCount":75},[],{"trials":4366,"activeCount":75},[],{"trials":4368,"activeCount":75},[],{"trials":4370,"activeCount":75},[4371,4375],{"nctId":4270,"briefTitle":4271,"status":81,"phases":4372,"completion":3556,"start":775,"enrollment":4273,"conditions":4373,"interventions":4374},[],[20],[4276,4277,4240],{"nctId":4300,"briefTitle":4301,"status":134,"phases":4376,"primaryCompletion":1652,"completion":1652,"start":1652,"enrollment":4303,"conditions":4377,"interventions":4378},[],[3188],[4306,4279,4307,4277],{"intervention":460,"totalTrials":187,"cells":4380},{"EARLY_PHASE1":4381,"PHASE1":4383,"PHASE2":4385,"PHASE3":4391,"PHASE4":4393,"NA":4395},{"trials":4382,"activeCount":75},[],{"trials":4384,"activeCount":75},[],{"trials":4386,"activeCount":75},[4387],{"nctId":1312,"briefTitle":1313,"status":81,"phases":4388,"primaryCompletion":1315,"completion":1316,"start":1317,"enrollment":1318,"conditions":4389,"interventions":4390},[64],[29,1320],[460,1322,1305,115],{"trials":4392,"activeCount":75},[],{"trials":4394,"activeCount":75},[],{"trials":4396,"activeCount":75},[4397],{"nctId":453,"briefTitle":454,"status":431,"phases":4398,"completion":456,"start":457,"enrollment":75,"conditions":4399,"interventions":4400},[67],[20],[460,95,100],{"intervention":4402,"totalTrials":183,"cells":4403},"Individual Patient TCR-Transduced PBL",{"EARLY_PHASE1":4404,"PHASE1":4406,"PHASE2":4408,"PHASE3":4410,"PHASE4":4412,"NA":4414},{"trials":4405,"activeCount":75},[],{"trials":4407,"activeCount":75},[],{"trials":4409,"activeCount":75},[],{"trials":4411,"activeCount":75},[],{"trials":4413,"activeCount":75},[],{"trials":4415,"activeCount":75},[4416],{"nctId":4417,"briefTitle":4418,"status":445,"phases":4419,"conditions":4420,"interventions":4421},"NCT04194190","A Single Patient Will be Treated With Individual Patient TCR-Transduced PBL",[],[],[4402],{"intervention":4423,"totalTrials":183,"cells":4424},"Levofloxacin",{"EARLY_PHASE1":4425,"PHASE1":4427,"PHASE2":4429,"PHASE3":4431,"PHASE4":4433,"NA":4435},{"trials":4426,"activeCount":75},[],{"trials":4428,"activeCount":75},[],{"trials":4430,"activeCount":75},[],{"trials":4432,"activeCount":75},[],{"trials":4434,"activeCount":75},[],{"trials":4436,"activeCount":75},[4437],{"nctId":4438,"briefTitle":4439,"status":81,"phases":4440,"primaryCompletion":4441,"completion":4442,"start":4443,"enrollment":4444,"conditions":4445,"interventions":4447},"NCT04639817","Trimethoprim-Sulfamethoxazole vs Levofloxacin as Targeted Therapy for Stenotrophomonas Maltophilia Infections: a Retrospective Cohort Study",[],"2021-01-31","2021-04-27","2020-08-14",1621,[4446],"Stenotrophomonas Infection",[4423,4448],"trimethoprim-sulfamethoxazole",{"intervention":4448,"totalTrials":183,"cells":4450},{"EARLY_PHASE1":4451,"PHASE1":4453,"PHASE2":4455,"PHASE3":4457,"PHASE4":4459,"NA":4461},{"trials":4452,"activeCount":75},[],{"trials":4454,"activeCount":75},[],{"trials":4456,"activeCount":75},[],{"trials":4458,"activeCount":75},[],{"trials":4460,"activeCount":75},[],{"trials":4462,"activeCount":75},[4463],{"nctId":4438,"briefTitle":4439,"status":81,"phases":4464,"primaryCompletion":4441,"completion":4442,"start":4443,"enrollment":4444,"conditions":4465,"interventions":4466},[],[4446],[4423,4448],{"intervention":4468,"totalTrials":183,"cells":4469},"ABC\u002FGen-Probe\u002FChiron HIV-1\u002FHCV 001",{"EARLY_PHASE1":4470,"PHASE1":4472,"PHASE2":4474,"PHASE3":4476,"PHASE4":4478,"NA":4480},{"trials":4471,"activeCount":75},[],{"trials":4473,"activeCount":75},[],{"trials":4475,"activeCount":75},[],{"trials":4477,"activeCount":75},[],{"trials":4479,"activeCount":75},[],{"trials":4481,"activeCount":75},[4482],{"nctId":4483,"briefTitle":4484,"status":81,"phases":4485,"completion":401,"start":1425,"enrollment":4486,"conditions":4487,"interventions":4489},"NCT00004846","Nucleic Acid Amplification Testing (NAT) of Blood Donors for HCV and HIV",[],30000,[4488,2669],"Hepatitis C",[4468],{"intervention":4491,"totalTrials":183,"cells":4492},"protein expression analysis",{"EARLY_PHASE1":4493,"PHASE1":4495,"PHASE2":4497,"PHASE3":4499,"PHASE4":4501,"NA":4503},{"trials":4494,"activeCount":75},[],{"trials":4496,"activeCount":75},[],{"trials":4498,"activeCount":75},[],{"trials":4500,"activeCount":75},[],{"trials":4502,"activeCount":75},[],{"trials":4504,"activeCount":75},[4505],{"nctId":4506,"briefTitle":4507,"status":81,"phases":4508,"completion":3186,"start":1875,"enrollment":4509,"conditions":4510,"interventions":4511},"NCT00899691","Study of Hair Samples From Patients With Cancer",[],190,[17],[4491],{"intervention":4513,"totalTrials":183,"cells":4514},"Anthrax Immune Globulin",{"EARLY_PHASE1":4515,"PHASE1":4517,"PHASE2":4519,"PHASE3":4521,"PHASE4":4523,"NA":4525},{"trials":4516,"activeCount":75},[],{"trials":4518,"activeCount":75},[],{"trials":4520,"activeCount":75},[],{"trials":4522,"activeCount":75},[],{"trials":4524,"activeCount":75},[],{"trials":4526,"activeCount":75},[4527],{"nctId":4528,"briefTitle":4529,"status":81,"phases":4530,"completion":1301,"start":4531,"enrollment":4532,"conditions":4533,"interventions":4535},"NCT00031291","Plasmapheresis of Anthrax-Vaccinated Subjects for Production of Anthrax Immune Globulin",[],"2002-02",400,[4534],"Anthrax",[4513],{"intervention":4537,"totalTrials":183,"cells":4538},"Antibiotic",{"EARLY_PHASE1":4539,"PHASE1":4541,"PHASE2":4543,"PHASE3":4545,"PHASE4":4547,"NA":4549},{"trials":4540,"activeCount":75},[],{"trials":4542,"activeCount":75},[],{"trials":4544,"activeCount":75},[],{"trials":4546,"activeCount":75},[],{"trials":4548,"activeCount":75},[],{"trials":4550,"activeCount":75},[4551],{"nctId":4552,"briefTitle":4553,"status":431,"phases":4554,"primaryCompletion":4555,"completion":4555,"start":4556,"enrollment":75,"conditions":4557,"interventions":4561},"NCT04674410","Utility of Empiric Antibiotics for Non-intubated Novel Coronavirus Diseases 2019 Patients",[],"2023-12-31","2020-03-01",[4558,4559,4560],"Covid19","Coronavirus Infection","Pneumonia",[4537],{"intervention":4563,"totalTrials":183,"cells":4564},"bupropion hydrochloride",{"EARLY_PHASE1":4565,"PHASE1":4567,"PHASE2":4569,"PHASE3":4571,"PHASE4":4573,"NA":4575},{"trials":4566,"activeCount":75},[],{"trials":4568,"activeCount":75},[],{"trials":4570,"activeCount":75},[],{"trials":4572,"activeCount":75},[],{"trials":4574,"activeCount":75},[],{"trials":4576,"activeCount":75},[4577],{"nctId":4578,"briefTitle":4579,"status":81,"phases":4580,"completion":4265,"start":84,"conditions":4581,"interventions":4583},"NCT00079469","Bupropion and Counseling With or Without Contingency Management to Enhance Smoking Cessation in Treating Cancer Survivors Who Continue to Smoke",[67],[4582,17],"Cancer Survivor",[4563],{"intervention":4585,"totalTrials":183,"cells":4586},"Linezolid",{"EARLY_PHASE1":4587,"PHASE1":4589,"PHASE2":4591,"PHASE3":4593,"PHASE4":4595,"NA":4597},{"trials":4588,"activeCount":75},[],{"trials":4590,"activeCount":75},[],{"trials":4592,"activeCount":75},[],{"trials":4594,"activeCount":75},[],{"trials":4596,"activeCount":75},[],{"trials":4598,"activeCount":75},[4599],{"nctId":4600,"briefTitle":4601,"status":4602,"phases":4603,"primaryCompletion":4604,"completion":4605,"start":4606,"enrollment":178,"conditions":4607,"interventions":4614},"NCT06126263","Adjunctive Clindamycin Versus Linezolid for β-lactam Treated Patients With Invasive Group A Streptococcal Infections","UNKNOWN",[],"2024-04-30","2024-06-30","2023-01-01",[4608,4609,4610,4611,4612,4613],"Streptococcal Sepsis","Invasive Group A Beta-Haemolytic Streptococcal Disease","Necrotizing Soft Tissue Infection","Infection, Bloodstream","Infection, Bacterial","Streptococcal Toxic Shock Syndrome",[4585,4615],"Clindamycin",{"intervention":4615,"totalTrials":183,"cells":4617},{"EARLY_PHASE1":4618,"PHASE1":4620,"PHASE2":4622,"PHASE3":4624,"PHASE4":4626,"NA":4628},{"trials":4619,"activeCount":75},[],{"trials":4621,"activeCount":75},[],{"trials":4623,"activeCount":75},[],{"trials":4625,"activeCount":75},[],{"trials":4627,"activeCount":75},[],{"trials":4629,"activeCount":75},[4630],{"nctId":4600,"briefTitle":4601,"status":4602,"phases":4631,"primaryCompletion":4604,"completion":4605,"start":4606,"enrollment":178,"conditions":4632,"interventions":4633},[],[4608,4609,4610,4611,4612,4613],[4585,4615],{"intervention":449,"totalTrials":183,"cells":4635},{"EARLY_PHASE1":4636,"PHASE1":4638,"PHASE2":4640,"PHASE3":4642,"PHASE4":4644,"NA":4646},{"trials":4637,"activeCount":75},[],{"trials":4639,"activeCount":75},[],{"trials":4641,"activeCount":75},[],{"trials":4643,"activeCount":75},[],{"trials":4645,"activeCount":75},[],{"trials":4647,"activeCount":75},[4648],{"nctId":443,"briefTitle":444,"status":445,"phases":4649,"conditions":4650,"interventions":4651},[],[],[449,268,269,450,451],{"intervention":451,"totalTrials":183,"cells":4653},{"EARLY_PHASE1":4654,"PHASE1":4656,"PHASE2":4658,"PHASE3":4660,"PHASE4":4662,"NA":4664},{"trials":4655,"activeCount":75},[],{"trials":4657,"activeCount":75},[],{"trials":4659,"activeCount":75},[],{"trials":4661,"activeCount":75},[],{"trials":4663,"activeCount":75},[],{"trials":4665,"activeCount":75},[4666],{"nctId":443,"briefTitle":444,"status":445,"phases":4667,"conditions":4668,"interventions":4669},[],[],[449,268,269,450,451],{"intervention":4276,"totalTrials":183,"cells":4671},{"EARLY_PHASE1":4672,"PHASE1":4674,"PHASE2":4676,"PHASE3":4678,"PHASE4":4680,"NA":4682},{"trials":4673,"activeCount":75},[],{"trials":4675,"activeCount":75},[],{"trials":4677,"activeCount":75},[],{"trials":4679,"activeCount":75},[],{"trials":4681,"activeCount":75},[],{"trials":4683,"activeCount":75},[4684],{"nctId":4270,"briefTitle":4271,"status":81,"phases":4685,"completion":3556,"start":775,"enrollment":4273,"conditions":4686,"interventions":4687},[],[20],[4276,4277,4240],{"intervention":4306,"totalTrials":183,"cells":4689},{"EARLY_PHASE1":4690,"PHASE1":4692,"PHASE2":4694,"PHASE3":4696,"PHASE4":4698,"NA":4700},{"trials":4691,"activeCount":75},[],{"trials":4693,"activeCount":75},[],{"trials":4695,"activeCount":75},[],{"trials":4697,"activeCount":75},[],{"trials":4699,"activeCount":75},[],{"trials":4701,"activeCount":75},[4702],{"nctId":4300,"briefTitle":4301,"status":134,"phases":4703,"primaryCompletion":1652,"completion":1652,"start":1652,"enrollment":4303,"conditions":4704,"interventions":4705},[],[3188],[4306,4279,4307,4277]]